<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancers (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Cancers (Basel)</journal-id><journal-id journal-id-type="publisher-id">cancers</journal-id><journal-title-group><journal-title>Cancers</journal-title></journal-title-group><issn pub-type="epub">2072-6694</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7408986</article-id><article-id pub-id-type="doi">10.3390/cancers12071860</article-id><article-id pub-id-type="publisher-id">cancers-12-01860</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Tumor-Associated Neutrophils Dampen Adaptive Immunity and Promote Cutaneous Squamous Cell Carcinoma Development</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Khou</surname><given-names>Sokchea</given-names></name><xref ref-type="aff" rid="af1-cancers-12-01860">1</xref><xref ref-type="author-notes" rid="fn1-cancers-12-01860">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7156-272X</contrib-id><name><surname>Popa</surname><given-names>Alexandra</given-names></name><xref ref-type="aff" rid="af1-cancers-12-01860">1</xref><xref ref-type="aff" rid="af2-cancers-12-01860">2</xref><xref ref-type="author-notes" rid="fn1-cancers-12-01860">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9687-4164</contrib-id><name><surname>Luci</surname><given-names>Carmelo</given-names></name><xref ref-type="aff" rid="af1-cancers-12-01860">1</xref><xref ref-type="aff" rid="af3-cancers-12-01860">3</xref><xref ref-type="author-notes" rid="fn2-cancers-12-01860">&#x02021;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8808-8152</contrib-id><name><surname>Bihl</surname><given-names>Franck</given-names></name><xref ref-type="aff" rid="af1-cancers-12-01860">1</xref><xref ref-type="author-notes" rid="fn2-cancers-12-01860">&#x02021;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7440-5495</contrib-id><name><surname>Meghraoui-Kheddar</surname><given-names>Aida</given-names></name><xref ref-type="aff" rid="af1-cancers-12-01860">1</xref></contrib><contrib contrib-type="author"><name><surname>Bourdely</surname><given-names>Pierre</given-names></name><xref ref-type="aff" rid="af1-cancers-12-01860">1</xref><xref ref-type="aff" rid="af4-cancers-12-01860">4</xref></contrib><contrib contrib-type="author"><name><surname>Salavagione</surname><given-names>Emie</given-names></name><xref ref-type="aff" rid="af1-cancers-12-01860">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9482-1755</contrib-id><name><surname>Cosson</surname><given-names>Estelle</given-names></name><xref ref-type="aff" rid="af1-cancers-12-01860">1</xref></contrib><contrib contrib-type="author"><name><surname>Rubod</surname><given-names>Alain</given-names></name><xref ref-type="aff" rid="af1-cancers-12-01860">1</xref></contrib><contrib contrib-type="author"><name><surname>Cazareth</surname><given-names>Julie</given-names></name><xref ref-type="aff" rid="af1-cancers-12-01860">1</xref></contrib><contrib contrib-type="author"><name><surname>Barbry</surname><given-names>Pascal</given-names></name><xref ref-type="aff" rid="af1-cancers-12-01860">1</xref></contrib><contrib contrib-type="author"><name><surname>Mari</surname><given-names>Bernard</given-names></name><xref ref-type="aff" rid="af1-cancers-12-01860">1</xref></contrib><contrib contrib-type="author"><name><surname>Rezzonico</surname><given-names>Roger</given-names></name><xref ref-type="aff" rid="af1-cancers-12-01860">1</xref></contrib><contrib contrib-type="author"><name><surname>Anju&#x000e8;re</surname><given-names>Fabienne</given-names></name><xref ref-type="aff" rid="af1-cancers-12-01860">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-8213-3947</contrib-id><name><surname>Braud</surname><given-names>Veronique M.</given-names></name><xref ref-type="aff" rid="af1-cancers-12-01860">1</xref><xref rid="c1-cancers-12-01860" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-cancers-12-01860"><label>1</label>Institut de Pharmacologie Mol&#x000e9;culaire et Cellulaire, Centre National de la Recherche Scientifique, Universit&#x000e9; C&#x000f4;te d&#x02019;Azur, UMR7275, 06560 Valbonne, Sophia Antipolis, France; <email>khou@ohsu.edu</email> (S.K.); <email>apopa@cemm.at</email> (A.P.); <email>Carmelo.Luci@unice.fr</email> (C.L.); <email>bihl@ipmc.cnrs.fr</email> (F.B.); <email>meghraoui@ipmc.cnrs.fr</email> (A.M.-K.); <email>pierre.bourdely@kcl.ac.uk</email> (P.B.); <email>emiesalavagione@gmail.com</email> (E.S.); <email>cosson@ipmc.cnrs.fr</email> (E.C.); <email>a.rubod@laposte.net</email> (A.R.); <email>cazareth@ipmc.cnrs.fr</email> (J.C.); <email>barbry@ipmc.cnrs.fr</email> (P.B.); <email>mari@ipmc.cnrs.fr</email> (B.M.); <email>rezzonico@ipmc.cnrs.fr</email> (R.R.); <email>anjuere@ipmc.cnrs.fr</email> (F.A.)</aff><aff id="af2-cancers-12-01860"><label>2</label>CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, 1090 Vienna, Austria</aff><aff id="af3-cancers-12-01860"><label>3</label>C3M, INSERM U1065, Universit&#x000e9; C&#x000f4;te d&#x02019;Azur, 06204 Nice, France</aff><aff id="af4-cancers-12-01860"><label>4</label>Laboratory of Phagocyte Immunobiology, Peter Gorer Department of Immunobiology, Centre for Inflammation Biology and Cancer Immunology, King&#x02019;s College London, London SE1 1UL, UK</aff><author-notes><corresp id="c1-cancers-12-01860"><label>*</label>Correspondence: <email>braud@ipmc.cnrs.fr</email></corresp><fn id="fn1-cancers-12-01860"><label>&#x02020;</label><p>These authors contributed equally to the work as first authors.</p></fn><fn id="fn2-cancers-12-01860"><label>&#x02021;</label><p>These authors contributed equally to the work as second authors.</p></fn></author-notes><pub-date pub-type="epub"><day>10</day><month>7</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>7</month><year>2020</year></pub-date><volume>12</volume><issue>7</issue><elocation-id>1860</elocation-id><history><date date-type="received"><day>11</day><month>6</month><year>2020</year></date><date date-type="accepted"><day>08</day><month>7</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Cutaneous squamous cell carcinoma (cSCC) development has been linked to immune dysfunctions but the mechanisms are still unclear. Here, we report a progressive infiltration of tumor-associated neutrophils (TANs) in precancerous and established cSCC lesions from chemically induced skin carcinogenesis. Comparative in-depth gene expression analyses identified a predominant protumor gene expression signature of TANs in lesions compared to their respective surrounding skin. In addition, in vivo depletion of neutrophils delayed tumor growth and significantly increased the frequency of proliferating IFN-&#x003b3; (interferon-&#x003b3;)-producing CD8+ T cells. Mechanisms that limited antitumor responses involved high arginase activity, production of reactive oxygen species (ROS) and nitrite (NO), and the expression of programmed death-ligand 1 (PD-L1) on TAN, concomitantly with an induction of PD-1 on CD8<sup>+</sup> T cells, which correlated with tumor size. Our data highlight the relevance of targeting neutrophils and PD-L1-PD-1 (programmed death-1) interaction in the treatment of cSCC.</p></abstract><kwd-group><kwd>neutrophils</kwd><kwd>cutaneous squamous cell carcinoma</kwd><kwd>PD-1</kwd><kwd>PD-L1</kwd><kwd>gene expression profile</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-cancers-12-01860"><title>1. Introduction</title><p>Cutaneous squamous cell carcinoma (cSCC) is the second most common non-melanoma skin cancer, which is associated with alterations in immunity that favor inflammation and tumor development [<xref rid="B1-cancers-12-01860" ref-type="bibr">1</xref>]. cSCCs are generally cured with surgery, but they can reach a stage of advanced invasive disease associated with extremely rapid local relapse, for which no efficient therapy has been approved so far. Antitumor activities of immune cells have been shown to be central to immune surveillance of the skin. Indeed, immunosuppressed organ transplant patients with defective T cell responses display a high incidence of cSCC [<xref rid="B2-cancers-12-01860" ref-type="bibr">2</xref>] and high numbers of regulatory T cells are detected in these tumors [<xref rid="B3-cancers-12-01860" ref-type="bibr">3</xref>]. In addition, when CD8+ T cells, &#x003b3;&#x003b4; T cells, and natural killer (NK) cells are rendered anergic by downregulation of NKG2D induced by high expression of its ligands on tumors, increased cancer incidence is observed [<xref rid="B4-cancers-12-01860" ref-type="bibr">4</xref>]. The reduction of DMBA/PMA (7,12-dimethylbenz[a]anthracene /phorbol 12-myristate 13-acetate) skin carcinogenesis in CXCR2&#x02212;/&#x02212; (C-X-C motif chemokine receptor 2) mice also suggests that myeloid suppressor cells play a role, but their full characterization has not been done yet [<xref rid="B5-cancers-12-01860" ref-type="bibr">5</xref>]. This is consistent with high-risk cSCC patients harboring an increased number of circulating and tumor-resident neutrophils [<xref rid="B6-cancers-12-01860" ref-type="bibr">6</xref>].</p><p>Neutrophils are highly abundant immune cells in the tumor microenvironment (TME) of a large number of cancers. They seem to regulate the initiation and progression of cancer, but their role is still a matter of controversy. In vivo depletion experiments led to either a failure to control tumor growth [<xref rid="B7-cancers-12-01860" ref-type="bibr">7</xref>,<xref rid="B8-cancers-12-01860" ref-type="bibr">8</xref>] or a reduction of tumor progression [<xref rid="B9-cancers-12-01860" ref-type="bibr">9</xref>]. Both antitumor and protumor functions have been assigned to tumor-associated neutrophils (TANs), with this functional plasticity being regulated by factors of the TME [<xref rid="B10-cancers-12-01860" ref-type="bibr">10</xref>,<xref rid="B11-cancers-12-01860" ref-type="bibr">11</xref>,<xref rid="B12-cancers-12-01860" ref-type="bibr">12</xref>]. TGF-&#x003b2; (Transforming growth factor beta) promotes protumor (N2) TAN while IFN-&#x003b2; and a lack of TGF-&#x003b2; favor antitumor (N1) TAN [<xref rid="B9-cancers-12-01860" ref-type="bibr">9</xref>,<xref rid="B13-cancers-12-01860" ref-type="bibr">13</xref>]. In humans, a meta-analysis of gene expression signatures among 39 human malignancies revealed that within the leukocyte population in the tumor microenvironment, polymorphonuclear (PMN) cells have been linked to the most adverse prognosis [<xref rid="B14-cancers-12-01860" ref-type="bibr">14</xref>]. The blood neutrophil-to-lymphocyte ratio (NLR) has also been proposed as a prognostic factor, with a high NLR associated with poor survival [<xref rid="B15-cancers-12-01860" ref-type="bibr">15</xref>]. However, a consensus on the classification of neutrophil subsets is lacking. While the capacity to kill or inhibit the growth of tumor cells is endorsed by N1 TAN, promotion of extracellular matrix remodeling, angiogenesis, cancer cell invasion, metastasis, and immune suppression are attributed to N2 TAN, also named PMN-myeloid-derived suppressor cells (PMN-MDSCs) [<xref rid="B16-cancers-12-01860" ref-type="bibr">16</xref>,<xref rid="B17-cancers-12-01860" ref-type="bibr">17</xref>]. Their phenotype largely overlaps and may even represent a continuum of states rather than clear distinct subsets [<xref rid="B18-cancers-12-01860" ref-type="bibr">18</xref>].</p><p>Because high-risk cSCC in patients is associated with an increased number of circulating and tumor-resident neutrophils [<xref rid="B6-cancers-12-01860" ref-type="bibr">6</xref>], we undertook a study to fully characterize TAN&#x02019;s phenotypes and functional roles in cSCC. A key issue to consider is the plasticity of cells in various microenvironments. This is particularly true for neutrophils, as their transcriptomic profiles have been found to be highly divergent when analyzed in the blood, bone marrow (BM), spleen, and tumor [<xref rid="B19-cancers-12-01860" ref-type="bibr">19</xref>,<xref rid="B20-cancers-12-01860" ref-type="bibr">20</xref>,<xref rid="B21-cancers-12-01860" ref-type="bibr">21</xref>]. We therefore compared neutrophils isolated from precancerous lesions or established cSCC induced by a DMBA/PMA treatment [<xref rid="B22-cancers-12-01860" ref-type="bibr">22</xref>] and from the orthotopic implantation of a DMBA/PMA-derived SCC cell line, mSCC38, in the skin dermis [<xref rid="B23-cancers-12-01860" ref-type="bibr">23</xref>], with neutrophils isolated from the skin surrounding these tumors. We show that the majority of TANs within precancerous lesions and cSCC display protumor functions contrary to neutrophils isolated from the surrounding skin. We also define key features of protumor TANs in cSCC that highlight the functional relevance of targeting neutrophils in this cancer.</p></sec><sec sec-type="results" id="sec2-cancers-12-01860"><title>2. Results</title><sec id="sec2dot1-cancers-12-01860"><title>2.1. The Local Microenvironment of Cutaneous Squamous Cell Carcinoma Imprints Tumor-Associated Neutrophils Towards a Protumor Phenotype</title><p>Application of DMBA together with PMA on mouse skin is a widely used experimental model to study skin carcinogenesis [<xref rid="B24-cancers-12-01860" ref-type="bibr">24</xref>]. This model accurately mimics the different stages of skin carcinoma development in humans, by inducing papilloma, which can further develop into invasive cSCC upon PMA stimulation (<xref ref-type="app" rid="app1-cancers-12-01860">Figure S1A</xref>). To assess the role of TAN in cSCC, we focused our study on Gr-1<sup>bright</sup>/Ly6G<sup>+</sup> neutrophils that extravagated into tissue, either within the skin surrounding precancerous lesions (papilloma skin) and established carcinomas (tumor skin), or those infiltrating the precancerous lesions (papilloma) and carcinomas (tumor). We detected a significant and progressive increase of the proportion of neutrophils within papillomas and tumors compared to the surrounding skin, with TAN accounting for 30&#x02013;80% of tumor-infiltrating CD45<sup>+</sup> cells (<xref ref-type="fig" rid="cancers-12-01860-f001">Figure 1</xref>A). We purified these neutrophils by flow cytometry (<xref ref-type="app" rid="app1-cancers-12-01860">Figure S1B</xref>) and performed unbiased gene expression array analysis to investigate their molecular signatures throughout cSCC development. These cell-sorted Gr-1<sup>bright</sup> cells exclusively expressed Ly6G, indicating they were neutrophils and not monocytes (<xref ref-type="app" rid="app1-cancers-12-01860">Figure S1C</xref>) [<xref rid="B25-cancers-12-01860" ref-type="bibr">25</xref>]. In addition, we excluded eosinophil contamination as eosinophil peroxidase encoded by <italic>Epx</italic> (eosinophil peroxidase) was not found to be expressed in the gene signature (<xref ref-type="app" rid="app1-cancers-12-01860">Figure S1D</xref>) [<xref rid="B26-cancers-12-01860" ref-type="bibr">26</xref>]. Principal component analysis (PCA) of the 15% most variable probe sets revealed a high reproducibility across replicates and a clear segregation according to biological condition (<xref ref-type="fig" rid="cancers-12-01860-f001">Figure 1</xref>B). The first principal component axis (PC1), the one explaining the largest percentage of variability (69.05%), separated the surrounding skin from cancer lesion samples. The identity of papilloma versus tumor stages was illustrated by the PC2, explaining 15.76% of the variability. The unique gene expression signature of each cell origin was further highlighted in the hierarchical clustering (<xref ref-type="app" rid="app1-cancers-12-01860">Figure S1E</xref>).</p><p>We next examined the differentially expressed genes (DEGs) across pairwise comparisons (<xref ref-type="fig" rid="cancers-12-01860-f001">Figure 1</xref>C). The most divergent contrast was the comparison of the tumor with its control tumor skin, yielding 2045 DEGs, followed by the comparison of papilloma with control papilloma skin, yielding 1528 DEGs. In these two contrasts, a majority of DEGs were upregulated. To a lesser extent, we observed 235 and 144 differentially modulated genes for the contrasts of tumor versus papilloma and tumor skin versus papilloma skin, respectively. In order to compare the modulation between lesions versus skin controls, across the papilloma and tumor stages, we performed the genuine association of expression profiles (GENAS) method from the limma R package. We compared the log fold changes between these two most divergent contrasts on the totality of probe sets, without setting differential expression cutoffs (<xref ref-type="app" rid="app1-cancers-12-01860">Figure S1F</xref>). The GENAS analysis yielded a strong biological correlation coefficient of 0.76 (<italic>p</italic> &#x0003c; 0.001), indicating that TAN gene modulation onset takes place at the papilloma stage and follows a similar trend in the tumor.</p><p>Then, to apprehend the biological processes and molecular functions associated with TANs in the context of cutaneous carcinoma pathogenesis, we performed a core analysis of the DEGs we obtained using ingenuity pathways analysis (IPA). As shown in <xref ref-type="fig" rid="cancers-12-01860-f001">Figure 1</xref>D, TGF-&#x003b2;, TNF-&#x003b1;, and IFN-&#x003b3; were the most significantly activated upstream regulators in lesions compared to the surrounding skin. These cytokines have been associated with protumorigenic phenotypes [<xref rid="B9-cancers-12-01860" ref-type="bibr">9</xref>,<xref rid="B27-cancers-12-01860" ref-type="bibr">27</xref>,<xref rid="B28-cancers-12-01860" ref-type="bibr">28</xref>,<xref rid="B29-cancers-12-01860" ref-type="bibr">29</xref>], suggesting that the cSCC microenvironment favors the tumor-promoting TAN phenotype. Consistent with this observation, the analysis of the canonical pathways enriched and modulated in at least one of the three contrasts revealed that CXCL-8 (IL-8) signaling was the most significantly activated pathway (<xref ref-type="app" rid="app1-cancers-12-01860">Figure S2A</xref>). This analysis also revealed that signaling through CXCR1 and CXCR2 receptors expressed by TANs resulted in the activation of specific functions promoting tumor growth, such as angiogenesis, endothelial cell migration, tumor invasion, and inflammation, but also in the inhibition of apoptosis, suggesting they harbor an increased lifespan in lesions (<xref ref-type="app" rid="app1-cancers-12-01860">Figure S2B</xref>). In mice, CXCL1 (C-X-C motif ligand 1) (KC) and CXCL2 (MIP-2, CXCL5 (LIX)) have been described as the functional homologues of human CXCL8 (IL-8) and they bind to CXCR1 and CXCR2 receptors, which we found to be expressed on mouse neutrophils (<xref ref-type="app" rid="app1-cancers-12-01860">Figure S2C</xref>). Neutrophil adhesion and chemotaxis were also activated, consistent with the well-known role of CXCL8 (IL-8) in the recruitment of neutrophils to the tumor site and in correlation with the increased proportion of TANs found in lesions compared to skin controls (<xref ref-type="fig" rid="cancers-12-01860-f001">Figure 1</xref>A). Altogether, these data highlighted the enhanced protumor functions of TAN in lesions compared to the surrounding skin.</p><p>We then clustered (K-means, ExpressCluster) the union of the differentially modulated genes across biological conditions (2166 probe sets) in order to identify specific gene expression signatures. We obtained 10 distinct clusters associated with a specific pattern of gene expression, revealing a clear separation between skin controls and lesions (<xref ref-type="fig" rid="cancers-12-01860-f001">Figure 1</xref>E). We further performed a Protein Analysis Through Evolutionary (PANTHER) enrichment analysis on the genes in each of the 10 clusters (<xref ref-type="app" rid="app1-cancers-12-01860">Figure S3</xref>). With this approach, we could retrieve both shared and specific functions of TAN and link them to localization in skin or lesions and to stages of carcinogenesis. The GO (gene ontology) enrichments revealed that the main features of TAN once infiltrated into papillomas were more specifically related to extracellular matrix remodeling (cluster 1 and 7), angiogenesis, and metastasis (cluster 7). When infiltrated into tumors, TANs were associated with active glycolysis (clusters 5, 8, and 9), increased survival, and immune suppression (cluster 10). TANs within papillomas and tumors also shared features related to repressed cytoskeleton reorganization controlling neutrophil functions (cluster 2), repressed leukocyte extravasation and migration (cluster 3), decrease of specific inflammatory and immune responses (cluster 3 and 4), and response to CXCL8 (IL-8) and TGF-&#x003b2; (cluster 6 and 7). Overall, a dominant protumor gene expression profile was observed. This can be illustrated by the significant upregulation of genes previously linked to protumorigenic phenotypes: <italic>Siglec5</italic> (encoding for Siglec F) in cluster 5, <italic>Cd274</italic> (encoding for PD-L1), <italic>Vegfa, Olr1</italic> (encoding for LOX-1) in cluster 6, <italic>Nos2</italic> in cluster 9, and <italic>Arg1</italic> in cluster 10 (<xref ref-type="fig" rid="cancers-12-01860-f001">Figure 1</xref>F) [<xref rid="B30-cancers-12-01860" ref-type="bibr">30</xref>,<xref rid="B31-cancers-12-01860" ref-type="bibr">31</xref>,<xref rid="B32-cancers-12-01860" ref-type="bibr">32</xref>,<xref rid="B33-cancers-12-01860" ref-type="bibr">33</xref>,<xref rid="B34-cancers-12-01860" ref-type="bibr">34</xref>]. This gene signature was also found to be significantly shared with the gene signature of protumor neutrophils infiltrating lung SCC [<xref rid="B35-cancers-12-01860" ref-type="bibr">35</xref>] (<xref ref-type="app" rid="app1-cancers-12-01860">Figure S4A</xref>). Pairwise comparisons of DEGs from our study with DEGs from TAN in lung SCC compared to circulating neutrophils [<xref rid="B35-cancers-12-01860" ref-type="bibr">35</xref>] identified a positive correlation with the contrasts of papillomas and tumors over surrounding skin, revealing that TANs from lung and cutaneous SCC share gene expression profiles (<xref ref-type="app" rid="app1-cancers-12-01860">Figure S4B</xref>).</p><p>Altogether, these analyses identify a massive infiltration of TANs in cSCC lesions, which display a dominant TAN&#x02019;s protumor gene expression profile that differ from their skin counterparts, highlighting a strong impact of the local microenvironment.</p></sec><sec id="sec2dot2-cancers-12-01860"><title>2.2. TAN Exhibit Heterogeneity in Their Phenotype and Exert Protumor Functions</title><p>To further characterize TAN in invasive cSCC, we took advantage of a recently established cSCC cell line mSCC38, which was generated from DMBA/PMA-treated mice [<xref rid="B23-cancers-12-01860" ref-type="bibr">23</xref>]. Orthotopic implantation of tumorigenic mSCC38 in the skin dermis promoted tumor growth in 100% of mice, over the course of ~30 days (<xref ref-type="fig" rid="cancers-12-01860-f002">Figure 2</xref>A), mimicking human invasive cSCC with invasion in the dermis (<xref ref-type="fig" rid="cancers-12-01860-f002">Figure 2</xref>B). Similar to the DMBA/PMA cSCC mouse model, the frequency of neutrophils increased in the grafted mSCC38 tumor over time (<xref ref-type="fig" rid="cancers-12-01860-f002">Figure 2</xref>C) and their proportion among infiltrating CD45+ immune cells was positively correlated with tumor volume (<xref ref-type="fig" rid="cancers-12-01860-f002">Figure 2</xref>D). Immunofluorescence staining localized neutrophils within the tumor bed (<xref ref-type="fig" rid="cancers-12-01860-f002">Figure 2</xref>E). Simultaneously, the frequency of neutrophils increased in the blood while no modulation was observed in the skin, spleen, and BM (<xref ref-type="app" rid="app1-cancers-12-01860">Figure S5A</xref>).</p><p>We used this mSCC38 mouse model to further investigate the phenotypic and functional diversity of TANs in cSCC. First, we evaluated the co-expression of a selected set of activation markers and cell surface receptors on live CD45+Ly6G+ neutrophils at a single-cell level by flow cytometry. t-distributed stochastic neighbor embedding (tSNE) analysis was used to create a single common map of neutrophils across all samples (bone marrow, spleen, blood, skin, and tumor) using markers identified in the above transcriptomic data (PD-L1 (CD274) and Siglec F) (<xref ref-type="fig" rid="cancers-12-01860-f001">Figure 1</xref>) and previously described as being modulated in neutrophils (CD54, CD62L, CD11b, CD80, CD11c) [<xref rid="B32-cancers-12-01860" ref-type="bibr">32</xref>,<xref rid="B34-cancers-12-01860" ref-type="bibr">34</xref>]. We could not include LOX1 because of a lack of available antibody. In an unsupervised manner, the t-SNE analysis arranged the bone marrow neutrophils in the lower left area of the map whereas spleen and blood neutrophils were in the central right and central left areas, respectively. The skin and tumor neutrophils shared the upper right area, with an additional specific location for tumor neutrophils in the upper left area (<xref ref-type="fig" rid="cancers-12-01860-f002">Figure 2</xref>F). This approach revealed the heterogeneity of neutrophils in tumors (TANs) compared to skin but also some similarities when both were compared to neutrophils from the spleen, blood, and bone marrow (<xref ref-type="fig" rid="cancers-12-01860-f002">Figure 2</xref>F). Individual expression of each marker per organ also reflected such heterogeneity (<xref ref-type="app" rid="app1-cancers-12-01860">Figure S5B</xref>). To identify the phenotype of TANs, we used the FlowSOM clustering tool to separate neutrophil subsets into 49 meta-clusters (MCs) (<xref ref-type="fig" rid="cancers-12-01860-f002">Figure 2</xref>F). The complete linkage hierarchical clustering of both samples and mean-centered MC cell proportions revealed four MCs highly abundant in tumor samples (<xref ref-type="fig" rid="cancers-12-01860-f002">Figure 2</xref>G, green gates); here, two of them were composed of PD-L1+ CD54<sup>+</sup> Siglec F+ neutrophils (MC11 and MC17) and the two others contained PD-L1+ CD54+ Siglec F<sup>&#x02212;</sup> neutrophils (MC31 and MC13) (<xref ref-type="fig" rid="cancers-12-01860-f002">Figure 2</xref>H), with mean proportions of 16.68 &#x000b1; 3.06% and 17.41 &#x000b1; 2.49%, respectively, in tumor samples (<xref ref-type="fig" rid="cancers-12-01860-f002">Figure 2</xref>I).</p><p>This computational analysis of the neutrophil phenotype revealed the PD-L1 marker as highly discriminant of TAN. Siglec F<sup>+</sup> neutrophils were previously found to accumulate in lung cancer, exerting protumor functions [<xref rid="B32-cancers-12-01860" ref-type="bibr">32</xref>]. By manual gating on cSCC neutrophil subsets, we found elevated proportions of TAN expressing both (14%) or one of the two markers, PD-L1 (15%) and Siglec F (15%), compared to skin with only 9% of PD-L1<sup>&#x02212;</sup> Siglec F<sup>+</sup> neutrophils. Spleen and BM neutrophils were negative for these markers (<xref ref-type="fig" rid="cancers-12-01860-f003">Figure 3</xref>A). Importantly, we found tumor size to correlate positively with the frequency of PD-L1<sup>+</sup> TAN, independently of Siglec F expression, and negatively with PD-L1<sup>&#x02212;</sup> Siglec F<sup>&#x02212;</sup> TAN (<xref ref-type="fig" rid="cancers-12-01860-f003">Figure 3</xref>B). These findings indicate that TAN can share both activation (CD54) and protumor markers (PD-L1, Siglec F) [<xref rid="B32-cancers-12-01860" ref-type="bibr">32</xref>,<xref rid="B34-cancers-12-01860" ref-type="bibr">34</xref>,<xref rid="B36-cancers-12-01860" ref-type="bibr">36</xref>] and that PD-L1 expression on TAN is associated with cSCC growth.</p><p>We further investigated whether TAN displayed functional properties contributing to tumor progression. Reactive oxygen and nitrite species are produced by neutrophils in various conditions of activation and are known to participate in tumor progression [<xref rid="B37-cancers-12-01860" ref-type="bibr">37</xref>]. The intracellular levels of the reduced form of nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP) are linked to the production of ROS. Using a fluorescent sensor, we measured a significant increase of intracellular levels of NAD(P)H (reduced nicotinamide adenine dinucleotide phosphate) in neutrophils infiltrating tumors compared to skin (<xref ref-type="fig" rid="cancers-12-01860-f003">Figure 3</xref>C). Spleen neutrophils behaved like TAN while BM neutrophils had NAD(P)H levels similar to skin neutrophils. Complementary to these results, we found an elevated production of ROS in TANs, lower levels in the spleen, and poor ROS production in the skin and BM (<xref ref-type="fig" rid="cancers-12-01860-f003">Figure 3</xref>D). The neutrophil subsets expressing PD-L1 also produced significantly more ROS than the subsets lacking PD-L1 (<xref ref-type="fig" rid="cancers-12-01860-f003">Figure 3</xref>E). Besides, we quantified the nitrites produced by highly purified neutrophils from tumors of mSCC38-bearing mice. Because of the paucity of neutrophils in the skin, we were not able to include the skin control, but we added neutrophils from the BM instead. As shown in <xref ref-type="fig" rid="cancers-12-01860-f003">Figure 3</xref>F, purified TANs produced significantly more nitrite (NO). Similarly, we quantified arginase activity in highly purified neutrophils and found significant increased activity of arginase in TANs (<xref ref-type="fig" rid="cancers-12-01860-f003">Figure 3</xref>G). Elevated NO and arginase activity in the mSCC38 model was consistent with our finding that transcription of <italic>Nos2</italic> and <italic>Arg1</italic> was increased in neutrophils from tumors and papillomas of DMBA/PMA-treated mice, compared to surrounding skin (<xref ref-type="fig" rid="cancers-12-01860-f001">Figure 1</xref>F). Such a phenotype also suggests that TANs may be involved in T cell immunosuppression in cSCC.</p></sec><sec id="sec2dot3-cancers-12-01860"><title>2.3. TANs Limit Antitumor CD8<sup>+</sup> T Cell Responses and Concomitant Upregulation of PD-L1 on TANs and PD-1 on CD8+ T Cells Participates in This Process</title><p>The above gene expression analysis and phenotypic and functional characterization suggested that TANs could promote cSCC. Consistent with this phenotype, we detected TGF-&#x003b2; within whole tumor cell lysates, with a 2-fold increase of TGF-&#x003b2; between days 15 and 28 (<xref ref-type="app" rid="app1-cancers-12-01860">Figure S6A</xref>). In order to directly demonstrate such a protumor role of TANs, we developed an in vivo protocol of neutrophil depletion that allowed the depletion of neutrophils in blood and in tumors (<xref ref-type="app" rid="app1-cancers-12-01860">Figure S6B,C</xref>). As shown in <xref ref-type="fig" rid="cancers-12-01860-f004">Figure 4</xref>A, the depletion of TANs significantly delayed mSCC38 growth as compared to isotype control IgG-treated mice.</p><p>Immune suppression is associated with protumor functions and has been attributed to N2 TAN and MDSC [<xref rid="B10-cancers-12-01860" ref-type="bibr">10</xref>,<xref rid="B16-cancers-12-01860" ref-type="bibr">16</xref>]. We therefore evaluated whether TAN promoted cSCC progression through the inhibition of antitumor CD8<sup>+</sup> T cell responses. We chose to address this question by directly monitoring ex vivo the outcome of TAN depletion on the CD8<sup>+</sup> T cell response. This choice of approach was guided by recent concerns over the accuracy of the in vitro assays used to measure suppression of T cell activity [<xref rid="B38-cancers-12-01860" ref-type="bibr">38</xref>]. The immunosuppressive activity of TAN was observed when comparing the CD8<sup>+</sup> T cell responses in tumors from mice that were treated either with anti-Ly6G or isotype IgG control (<xref ref-type="fig" rid="cancers-12-01860-f004">Figure 4</xref>B,C).</p><p>We did not find significant differences in the frequencies of CD3+CD8+ and CD3+CD4+ T cells, as well as Foxp3<sup>+</sup> CD25<sup>+</sup> regulatory T cells (Treg) and natural killer (NK) cells, among mSCC38-infiltrating CD45<sup>+</sup> immune cells (<xref ref-type="app" rid="app1-cancers-12-01860">Figure S6D&#x02013;F</xref>). By contrast, the frequencies of proliferating and IFN-&#x003b3;-producing CD3<sup>+</sup>CD8<sup>+</sup> T cells were significantly increased in the absence of neutrophils (<xref ref-type="fig" rid="cancers-12-01860-f004">Figure 4</xref>B,C). This immune suppression may result from a direct crosstalk between TAN and CD3+CD8+ T cells, as immunofluorescence staining of mSCC38 tumor sections identified neutrophils in contact with CD8+ T cells (<xref ref-type="fig" rid="cancers-12-01860-f004">Figure 4</xref>D).</p><p>Several mechanisms can be responsible for the inhibition of CD3+CD8+ T cell responses. We found that TAN showed a high arginase activity (<xref ref-type="fig" rid="cancers-12-01860-f003">Figure 3</xref>G) and high production of ROS and NO (<xref ref-type="fig" rid="cancers-12-01860-f003">Figure 3</xref>C&#x02013;F) that can limit CD8+ T cell responses. In addition, because we found PD-L1 to discriminate TANs from neutrophils of the skin, we investigated whether PD-L1-PD-1 interaction could also play a role. We analyzed the expression of PD-1 on T cells (<xref ref-type="fig" rid="cancers-12-01860-f004">Figure 4</xref>E) and detected highly significant increased frequencies of PD-1-expressing CD8+ and CD4+ T cells in the tumor (<italic>p</italic> &#x0003c; 0.0001). By contrast, no expression of PD-1 was detected on T cells from the spleen and lymph node of tumor-bearing mice. To further depict mechanisms that could sustain such a role, we investigated the effect of the tumor microenvironment on the induction of PD-L1 expression and on TAN survival. We prepared tumor-conditioned medium (TCM) and treated in vitro PD-L1-negative BM neutrophils from naive mice. TCM was able to induce PD-L1 on about 40% of neutrophils (<xref ref-type="fig" rid="cancers-12-01860-f004">Figure 4</xref>F and <xref ref-type="app" rid="app1-cancers-12-01860">Figure S7A</xref>). We then tested the impact of TGF-&#x003b2;, TNF-&#x003b1;, and IFN-&#x003b3; cytokines as we previously identified them as top upstream regulators in TAN from DMBA/PMA-treated mice and also GM-CSF (granulocyte-macrophage colony-stimulating factor), which was reported to induce PD-L1 [<xref rid="B39-cancers-12-01860" ref-type="bibr">39</xref>]. Treatment with IFN-&#x003b3;, TNF-&#x003b1;, and GM-CSF could induce PD-L1 with different efficiencies, with IFN-&#x003b3; being the most efficient and GM-CSF the least (<xref ref-type="app" rid="app1-cancers-12-01860">Figure S7A</xref>). TGF-&#x003b2; did not induce any PD-L1 expression on neutrophils. We confirmed the predominant role of IFN-&#x003b3; by depleting the TCM of IFN-&#x003b3; and found that the frequency of PD-L1+ neutrophils was decreased by half (<xref ref-type="fig" rid="cancers-12-01860-f004">Figure 4</xref>F). The TCM was also able to maintain neutrophils alive in this experimental setting (<xref ref-type="app" rid="app1-cancers-12-01860">Figure S7B</xref>), similarly to GM-CSF. This was in agreement with our previous observation from the gene expression profile of TANs from DMBA/PMA-treated mice, which showed that TANs displayed an increased lifespan compared to neutrophils in the surrounding skin (<xref ref-type="app" rid="app1-cancers-12-01860">Figure S2B</xref>).</p><p>Collectively, our data demonstrate that infiltrated TANs contribute to cSCC development by limiting effector CD8<sup>+</sup> T cell responses.</p></sec></sec><sec sec-type="discussion" id="sec3-cancers-12-01860"><title>3. Discussion</title><p>The observed increased infiltration of neutrophils in invasive cSCC in humans [<xref rid="B6-cancers-12-01860" ref-type="bibr">6</xref>] questions their role during cSCC development and relapse. To gain an understanding of their contribution, we provide here an extensive characterization of neutrophils infiltrating lesions and the surrounding skin throughout cSCC progression. Both gene expression signatures, and phenotypic and functional analyses showed that, once within lesions, TANs acquired protumorigenic phenotypes and immunosuppressive capacities that contribute to cSCC progression.</p><p>The recruitment of abundant numbers of neutrophils was observed in the mouse models of cSCC we studied, consistent with the human pathology [<xref rid="B6-cancers-12-01860" ref-type="bibr">6</xref>]. This may be a feature shared with squamous cell carcinomas in general, as depicted for lung SCCs enriched in TANs as compared to lung adenocarcinomas [<xref rid="B35-cancers-12-01860" ref-type="bibr">35</xref>,<xref rid="B40-cancers-12-01860" ref-type="bibr">40</xref>,<xref rid="B41-cancers-12-01860" ref-type="bibr">41</xref>]. Interestingly, we found a significant correlation between gene signatures of TAN from both cutaneous and lung SCC, suggesting that the immune contexture of SCC certainly favors neutrophil recruitment. This is illustrated by our finding that the top canonical pathway that was activated was the IL-8 signaling pathway. This confirmed a primary role of CXCR1/CXCR2 and their ligands in the recruitment of neutrophils from blood, in agreement with other cancer types [<xref rid="B5-cancers-12-01860" ref-type="bibr">5</xref>,<xref rid="B17-cancers-12-01860" ref-type="bibr">17</xref>,<xref rid="B42-cancers-12-01860" ref-type="bibr">42</xref>].</p><p>To study the impact of the TME, we chose to compare TANs to neutrophils within the skin surrounding the lesions. We speculated that as they were both recruited from blood, they were the most accurate controls. The study of the papilloma stage, which can be viewed as a precancerous step, together with the tumor stage allowed us to show that most of the impact of the TME already occurred at the papilloma stage. Nevertheless, we were also able to identify specific features of TANs at each stage of the carcinogenesis. We found that angiogenesis and extracellular matrix remodeling were functions primarily implemented by precancerous TANs and that immune suppression was predominantly completed at the tumor stage. This indicates that neutrophils are highly plastic, not only in distinct organs [<xref rid="B19-cancers-12-01860" ref-type="bibr">19</xref>,<xref rid="B20-cancers-12-01860" ref-type="bibr">20</xref>,<xref rid="B43-cancers-12-01860" ref-type="bibr">43</xref>] but also over the course of tumor progression. The comparison of TME versus surrounding skin also identified a prolonged lifespan of TAN within tumors, and in vitro cultures in the presence of TCM enhanced the survival of neutrophils. This sustained survival with TCM was also observed in other cancers [<xref rid="B39-cancers-12-01860" ref-type="bibr">39</xref>,<xref rid="B40-cancers-12-01860" ref-type="bibr">40</xref>] and we identified a role for GM-CSF in this process. This observation is reminiscent of the reduced rate of apoptosis of the circulating human low-density neutrophils (LDNs) compared to high-density neutrophils (HDNs) and reinforced the proposed link between LDNs and N2 TANs [<xref rid="B30-cancers-12-01860" ref-type="bibr">30</xref>,<xref rid="B44-cancers-12-01860" ref-type="bibr">44</xref>].</p><p>The observation that TANs predominantly harbor a protumorigenic phenotype in cSCC is shared with many cancers but also differs from others [<xref rid="B11-cancers-12-01860" ref-type="bibr">11</xref>,<xref rid="B14-cancers-12-01860" ref-type="bibr">14</xref>,<xref rid="B16-cancers-12-01860" ref-type="bibr">16</xref>]. Our study does not exclude the presence of minor subsets of neutrophils that favor antitumor responses, as reported in the early stages of lung cancer [<xref rid="B45-cancers-12-01860" ref-type="bibr">45</xref>] or in a murine carcinogen-induced sarcoma model [<xref rid="B8-cancers-12-01860" ref-type="bibr">8</xref>]. Hence, we detected higher levels of <italic>Nos2</italic> and <italic>GrzB</italic> transcripts in TANs, with both being associated with cytotoxic functions [<xref rid="B46-cancers-12-01860" ref-type="bibr">46</xref>,<xref rid="B47-cancers-12-01860" ref-type="bibr">47</xref>,<xref rid="B48-cancers-12-01860" ref-type="bibr">48</xref>]. We also found that TANs were heterogeneous in cSCC, with upregulation of some activation markers. Whether anti- and pro-tumor neutrophils could be differentiated by the level of activation still remains an open question [<xref rid="B9-cancers-12-01860" ref-type="bibr">9</xref>,<xref rid="B36-cancers-12-01860" ref-type="bibr">36</xref>]. In human studies, antitumor TANs have been shown to express a classically activated phenotype with upregulation of CD54 and downregulation of CD62L and CD16 [<xref rid="B40-cancers-12-01860" ref-type="bibr">40</xref>,<xref rid="B49-cancers-12-01860" ref-type="bibr">49</xref>] and protumor TANs also showed an activated immunosuppressive phenotype with upregulation of CD54 and PD-L1, similarly to our findings [<xref rid="B39-cancers-12-01860" ref-type="bibr">39</xref>]. IFN-&#x003b3; drove a high level of PD-L1, consistent with an adaptive resistance [<xref rid="B50-cancers-12-01860" ref-type="bibr">50</xref>,<xref rid="B51-cancers-12-01860" ref-type="bibr">51</xref>]. Further work is needed to get the full diversity of phenotypes and their relationships with PMN-MDSC and immature/mature neutrophils [<xref rid="B52-cancers-12-01860" ref-type="bibr">52</xref>,<xref rid="B53-cancers-12-01860" ref-type="bibr">53</xref>]. Already, comparison with lung SCC models suggests that conserved gene expression profiles can be found and that a continuum of states also characterizes neutrophil subsets [<xref rid="B18-cancers-12-01860" ref-type="bibr">18</xref>,<xref rid="B35-cancers-12-01860" ref-type="bibr">35</xref>].</p><p>A key observation in our study is that TANs in cSCC are actively involved in immune suppression, limiting CD8<sup>+</sup> T cell responses, and promoting cSCC growth. We investigated the immunosuppressive phenotype of TANs in vivo, in the complex context of tumor progression and immune response modulation. We demonstrated that a combination of immunosuppressive mechanisms was in place. TANs purified from cSCC tumors exhibited increased <italic>Arg1</italic> transcription as well as higher arginase activity, potentially leading to arginine depletion from the environment, a metabolite crucial for T cell effector function [<xref rid="B11-cancers-12-01860" ref-type="bibr">11</xref>,<xref rid="B16-cancers-12-01860" ref-type="bibr">16</xref>]. At the same time, we showed an increase of NO and ROS, both being able to act as intracellular signaling molecules to modulate T cell functions [<xref rid="B54-cancers-12-01860" ref-type="bibr">54</xref>]. Their contribution is likely to be local and hence, we did not find significant modulation of nitrite concentrations and arginase activity in whole tumor cell samples from mice depleted or not of neutrophils. Further work is needed to assess the full contribution of NO and ROS. Lastly, we found that TANs upregulated PD-L1 while CD8<sup>+</sup> T cells upregulated PD-1 in the TME. TANs can participate in the immune suppression of T cell responses via PD-L1-PD-1 immune checkpoint interaction, as indicated by the positive correlation between tumor size and frequencies of PD-L1+ TANs. This is consistent with recent studies, which demonstrated the contribution of both tumors and non-tumor cells expressing PD-L1 to the suppression of T cell responses [<xref rid="B55-cancers-12-01860" ref-type="bibr">55</xref>]. Interestingly, a recent phase 1 trial using cemiplimab that targets PD-1 was conducted in advanced cSCC. It induced a response in half of the patients and may be linked to PD-L1+ TAN infiltration [<xref rid="B56-cancers-12-01860" ref-type="bibr">56</xref>]. PD-L1 expression on TANs was reported in several cancers, such as head and neck squamous cell carcinoma, hepatocellular carcinoma, colon cancer, gastric cancer, and lung cancer, and may constitute targets for anti-immune checkpoint treatments [<xref rid="B55-cancers-12-01860" ref-type="bibr">55</xref>]. The effect of current anticancer immunotherapy treatments in combination with other molecules acting on TANs is also being examined and may provide valuable insights into TAN functions. This is well exemplified by Gemcitabine treatment, which selectively eliminated CD11b<sup>+</sup> Gr-1<sup>+</sup> cells and efficiently enhanced the efficacy of a combination of resiquimod immunomodulatory and PD-L1 blockade against a murine HNSCC tumor highly infiltrated by TANs [<xref rid="B57-cancers-12-01860" ref-type="bibr">57</xref>], or by c-MET (tyrosine-protein kinase Met) inhibitors, which enhanced anti-PD-1 treatment efficacy via blockade of neutrophil recruitment [<xref rid="B27-cancers-12-01860" ref-type="bibr">27</xref>]. Besides PD-L1, we evaluated the expression of Siglec F reported to be a protumor marker for TANs in lung adenocarcinomas [<xref rid="B32-cancers-12-01860" ref-type="bibr">32</xref>]. Siglec F was induced on a proportion of TANs in cSCC, either together with PD-L1 or alone, but its expression was not associated with ROS, nor correlated with tumor size in cSCC. Further characterization of TAN subsets is warranted to extend our understanding of their functions in cSCC development.</p></sec><sec id="sec4-cancers-12-01860"><title>4. Materials and Methods</title><sec id="sec4dot1-cancers-12-01860"><title>4.1. Mice</title><p>FVB/N wild-type (WT) mice (Charles River Laboratories, St Germain Nuelles, France) were bred and housed in specific pathogen-free conditions. Experiments were performed using 6&#x02013;7-week-old female FVB/N, in compliance with institutional guidelines and were approved by the regional committee for animal experimentation (reference MESR 2016112515599520; CIEPAL, Nice C&#x000f4;te d&#x02019;Azur, France).</p></sec><sec id="sec4dot2-cancers-12-01860"><title>4.2. In Vivo Tumor Growth</title><p>Multi-stage chemical carcinogenesis was induced as follows: 200 nmol of DMBA (Sigma-Aldrich, St Quentin Fallavier, France) dissolved in toluene (Merck Millipore, Molsheim, France) and further diluted in acetone were applied on the shaved back of mice at 6 and 13 weeks of age, together with the application twice weekly of 5 nmol of PMA (Sigma-Aldrich, St Quentin Fallavier, France) dissolved in acetone, from week 1 to week 18&#x02013;20. Mice were assessed for papilloma and tumor development throughout the treatment from week 10&#x02013;12 up to sacrifice in week 22. The mSCC38 tumor cell line was established from DMBA/PMA-induced sSCCs and maintained in DMEM (Dulbecco&#x02019;s Modified Eagle Medium) (Gibco-ThermoFisher Scientific, Courtaboeuf, France) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (GE Healthcare, Chicago, IL, USA), penicillin (100 U/mL), and streptomycin (100 &#x003bc;g/mL) (Gibco-ThermoFisher Scientific, Courtaboeuf, France). Then, 5 &#x000d7; 10<sup>5</sup> mSCC38 were intradermally injected in anesthetized mice after dorsal skin shaving. Tumor volume was measured manually using a ruler and calculated according to the ellipsoid formula: Volume = Length (mm) &#x000d7; Width (mm) &#x000d7; Height (mm) &#x000d7; (&#x003c0;/6).</p></sec><sec id="sec4dot3-cancers-12-01860"><title>4.3. In Vivo Neutrophil Depletion</title><p>Mice received intraperitoneal injection of 150 &#x003bc;g of either anti-Ly6G (clone 1A8) or isotype IgG control (clone 2A3) (BioXcell, Lebanon, NH, USA) one day before mSCC38 engraftment and continuously every three days. Neutrophil depletion was monitored by flow cytometry, in blood day 14 and 28, and in tumor at sacrifice.</p></sec><sec id="sec4dot4-cancers-12-01860"><title>4.4. Tissue Preparation and Cell Purification</title><p>Papillomas and tumors were enzymatically treated twice with collagenase IV (0.6 mg/mL) (Sigma-Aldrich, St Quentin Fallavier, France), dispase II (2.5 mg/mL), and DNase I (0.2 mg/mL) (Roche Diagnostic, Meylan, France) for 20 min at 37 &#x000b0;C and the skin surrounding cancerous lesions was treated twice with collagenase IV (0.6 mg/mL) for 20 min at 37 &#x000b0;C. Immune cells were enriched using a Percoll gradient centrifugation (GE Healthcare, Chicago, IL, USA). For DMBA/PMA-treated mice, isolated cells were incubated with 5 &#x003bc;g/mL anti-CD16/CD32 (2.4G2) to block Fc receptors prior to incubation with the following fluorescently labeled antibodies to CD3 (145-2C11), CD11c (HL3), CD45 (30-F11), CD45R/B220 (RA3-6B2), CD335/NKp46 (29A1.4), Gr-1 (RB6-8C5), Ly6C (AL-21), Ly6G (1A8), and MHCII (I-A/I-E) (2G9). For mSCC-38-bearing mice, isolated cells were enriched in CD45<sup>+</sup> cells using CD45-biotin antibody (BD Biosciences, Le Pont de Claix, France) and anti-biotin magnetic beads (Miltenyi Biotec, Paris, France) according to the manufacturer&#x02019;s instructions. Cells were then incubated with 5 &#x003bc;g/mL anti-CD16/CD32 (2.4G2) and stained with anti-CD11b (M1/70), anti-Ly6G (clone 1A8) antibodies, and live/dead marker (7-AAD). All antibodies and viability markers were purchased from BD Biosciences, Le Pont de Claix, France. Neutrophils were cell sorted on a BD FACSAria II&#x02122; (BD Biosciences, Le Pont de Claix, France). Purity after cell sorting was &#x0003e;98%.</p><p>Spleen and bone marrow (BM) cells flushed from mice femurs were homogenized into single-cell suspensions through a 70-&#x003bc;m nylon mesh. Blood was collected from the tail vein on heparin tubes. Red blood cells were lysed in ACK lysis buffer (150 mM NH4Cl, 10 mM KHCO3, 0.1 mM Na2 EDTA, pH 7.2). Neutrophils were enriched from BM cell suspensions using Histopaque-based density gradient centrifugation (Sigma Aldrich, St Quentin Fallavier, France).</p></sec><sec id="sec4dot5-cancers-12-01860"><title>4.5. RNA Isolation and Microarray Analysis</title><p>First, 50 to 700 ng total RNA were isolated from 0.01 to 2 million sorted cells using a micro RNAeasy kit according to the manufacturer&#x02019;s instructions (Qiagen, Courtaboeuf, France). Purity and quality were assessed with a Bioanalyser (Agilent Technologies, Les Ulis, France). Probes were synthesized from RNA with the LowInput QuickAmp Labeling Kit (Agilent Technologies, Les Ulis, France). cRNA with appropriate quality control were hybridized to SurePrint G3 Mouse GE 8x60K microarrays (Agilent Technologies, Les Ulis, France). Two or three biological replicates were performed for each experimental condition to obtain sufficient material. Neutrophils were purified from the skin surrounding papillomas (3 mice per experiment), skin surrounding tumors (5 mice per experiment), papillomas (a mean of 60 papillomas from 3 mice), and tumors (a mean of 12 tumors from 5 mice). The obtained microarray experimental data and associated microarray designs were deposited in the NCBI Gene Expression Omnibus (GEO) (<uri xlink:href="http://www.ncbi.nlm.nih.gov/geo/">http://www.ncbi.nlm.nih.gov/geo/</uri>) under the serial record number GSE133807. The raw data were quantile normalized using the Bioconductor package limma. The batch effect induced by the microarray chips was removed using the ComBat method. Gene expression was implemented with the limma package. The Benjamini&#x02013;Hochberg procedure was used to control the experiment-wise false discovery rate (FDR) from multiple testing procedures. We performed a principal component analysis (PCA) on the 15% most variable probe sets with a minimum log2 average expression of 6, selected with the PopulationDistances program from <uri xlink:href="http://cbdm.hms.harvard.edu/LabMembersPges/SD.html">http://cbdm.hms.harvard.edu/LabMembersPges/SD.html</uri>. Using a pairwise average-linkage method (GenePattern) (<uri xlink:href="http://www.broadinstitute.org/cancer/software/genepattern/">http://www.broadinstitute.org/cancer/software/genepattern/</uri>), a hierarchical clustering was performed on the same probe sets median centered across all samples. Differentially expressed probe sets were selected based on an average log2 expression level across all conditions of at least 6, an absolute log2-fold change &#x02265;1, and an adjusted <italic>p</italic> value &#x02264; 0.05. Further analyses were carried out using the Protein Analysis Through Evolutionary (PANTHER) database (<uri xlink:href="http://pantherdb.org">http://pantherdb.org</uri>) and QIAGEN&#x02019;s Ingenuity Pathway Analysis (IPA) tool, QIAGEN Redwood City (<uri xlink:href="http://www.qiagen.com/ingenuity">http://www.qiagen.com/ingenuity</uri>). A biological correlation coefficient between papilloma versus papilloma skin and tumor versus tumor skin comparisons was estimated using the Genuine Association of Gene Expression Profiles (GENAS) method implemented in the limma R package. A k-means ++ (z-norm) clustering was performed with the ExpressCluster software v1.3 (<uri xlink:href="http://cbdm.hms.harvard.edu/LabMembersPges/SD.html">http://cbdm.hms.harvard.edu/LabMembersPges/SD.html</uri>) on the union of differentially modulated genes between lesions and surrounding controls (a total of 2166 probe sets). For genes with multiple probe sets, the median intensity value was computed.</p></sec><sec id="sec4dot6-cancers-12-01860"><title>4.6. Flow Cytometry and Computational Analysis</title><p>Cell suspensions were incubated with anti-CD16/32 (2.4G2) to block Fc receptors. For flow cytometry surface labelling, cells were stained with antibodies against CD3 (145-2C11), CD4 (GK1.5 and RM4-5), CD8&#x003b1; (53-6.7), CD11b (M1/70), CD19 (1D3), CD25 (PC61), CD45 (30-F11), MHCII (M5/114.15.2), Gr1 (RB6-8C5), Ly6G (1A8), Ly6C (AL-21), NKp46 (29A1.4), Siglec F (E50-2440), CD274 (MIH5), CD62L (MEL-14), CD54 (3E2), CD80 (16-10A1), CD279 (J43) (BD Biosciences, Le Pont de Claix, France), CD11c (N418), (Biolegend, Amsterdam, The Netherlands), and live/dead markers: 7-AAD (BD Biosciences, Le Pont de Claix, France), Zombie Aqua, and Zombie NIR (Biolegend, Amsterdam, The Netherlands). For intracellular staining, cells were either stained after isolation or restimulated for 4 h at 37 &#x000b0;C in complete DMEM medium supplemented with 100 ng/mL PMA (Sigma-Aldrich, St Quentin Fallavier, France), 1 &#x003bc;g/mL ionomycin in the presence of GolgiStop, and GolgiPlug (BD Biosciences, Le Pont de Claix, France). Cells were fixed and permeabilized with either BD Cytofix/Cytoperm (BD Biosciences, Le Pont de Claix, France) for cytokine staining or Foxp3/Transcription Factor Staining Buffer Set (eBioscience, Paris, France) for nuclear staining. Antibodies against Ki67 (SolA15), IFN-&#x003b3; (XMG1.2) and Foxp3 (MF23) were used. Samples were acquired on a BD LSR Fortessa (BD Biosciences, Le Pont de Claix, France) and analyzed with DIVA V8, FlowJo V10 software (BD Biosciences, Le Pont de Claix, France) and a Cytobank platform (Beckman Coulter, Roissy, France). The visualization of t-Distributed Stochastic Neighbor Embedding (viSNE implementation of t-SNE) was used to automatically arrange cells according to their expression profile of the measured proteins and to visualize all cells in a 2-D map, where the position represents local phenotypic similarity. The analyzed neutrophils were embedded in a set of t-SNE axes designated as t-SNE-1 and t-SNE-2 according to the per-cell expression of CD11b, Ly-6G, CD62L, PD-L1 (CD274), CD54, and Siglec F. After dimensionality reduction with t-SNE, neutrophils were grouped in 50 meta-clusters that contained phenotypically homogenous cells using the computationally generated self-organized map with the FlowSOM algorithm.</p></sec><sec id="sec4dot7-cancers-12-01860"><title>4.7. Immunofluorescence</title><p>mSCC38 tumors were fixed in Antigenfix (Diapath, Martinengo, Italy) for 1 h at 4 &#x000b0;C, washed, and incubated in 30% sucrose (Sigma-Aldrich, St Quentin Fallavier, France) overnight at 4 &#x000b0;C. Fixed tumors were washed, embedded in OCT (Tissue-Tek, Villeneuve d&#x02019;Ascq, France), and frozen prior to cryostat sectioning. Next, 7-&#x003bc;m-thick cryostat tumor sections were blocked with 10% normal donkey serum in PBS, 2% BSA (Sigma-Aldrich, St Quentin Fallavier, France), 1% FBS, and 0.5% saponin (Sigma-Aldrich, St Quentin Fallavier, France) at room temperature (RT) for 1 h. Sections were stained overnight with primary antibody (purified anti-CD8 (53-6.7) or purified anti-CD31 (390) (BD Biosciences, Le Pont de Claix, France), followed by incubation for 2 h at RT with donkey anti-rat IgG-A594 (Invitrogen-ThermoFisher Scientific, Courtaboeuf, France). After extensive washes, sections were labeled with anti-Ly6G-FITC (1A8) for 1 h at RT. Nuclei staining was performed using Hoechst 33342 (ThermoFisher Scientific, Courtaboeuf, France) for 5 min at RT and sections were mounted with Prolong Diamond (ThermoFisher Scientific, Courtaboeuf, France). Slides were imaged with a LSM780 confocal microscope (Zeiss, Marly le Roi, France) and analyzed with Fiji software.</p></sec><sec id="sec4dot8-cancers-12-01860"><title>4.8. Oxidative Burst Assay</title><p>After surface staining, 500,000 cells were incubated for 15 min at 37 &#x000b0;C in buffer (PBS, 3% FBS, 5mM EDTA) supplemented with 1 &#x003bc;M Dihydrorhodamine (DHR) 123 and 50 &#x003bc;g/mL catalase (Sigma-Aldrich, St Quentin Fallavier, France). Cells were subsequently washed with PSE and the fluorescence intensity of DHR123 was read on a BD LSR Fortessa (BD Biosciences, Le Pont de Claix, France) and analyzed with DIVA V8 and FlowJo V10 software (BD Biosciences, Le Pont de Claix, France).</p></sec><sec id="sec4dot9-cancers-12-01860"><title>4.9. NADPH/NADP</title><p>After surface staining, 500,000 cells were incubated for 30 min at 37 &#x000b0;C in PBS supplemented with a JZL1707 NAD(P)H sensor according to the manufacturer&#x02019;s instructions (AAT Bioquest, Euromedex, Souffelweyersheim, France). Cells were subsequently washed with PBS and the fluorescence intensity of the JZL1707 NAD(P)H sensor was read in the PE channel on a SP6800 Spectral Cell Analyzer (Sony, Weybridge, UK) and analyzed with FlowJo V10 software (BD Biosciences, Le Pont de Claix, France).</p></sec><sec id="sec4dot10-cancers-12-01860"><title>4.10. NO (Nitrite) Quantification</title><p>First, 10<sup>6</sup> highly purified neutrophils were cultured for 24 h at 37 &#x000b0;C in DMEM without red phenol (Gibco-ThermoFisher Scientific, Courtaboeuf, France) supplemented with 10% FBS (GE Healthcare, Chicago, IL, USA), penicillin (100 U/mL), and streptomycin (100 &#x003bc;g/mL) (Gibco-ThermoFisher Scientific, Courtaboeuf, France). NO production was measured in the supernatant using Greiss reagent assay according to the manufacturer&#x02019;s instructions (Sigma Aldrich, St Quentin Fallavier, France). The absorbance was measured at 550 nm using a Multiskan FC plate reader (ThermoFisher Scientific, Courtaboeuf, France).</p></sec><sec id="sec4dot11-cancers-12-01860"><title>4.11. Arginase Activity Assay</title><p>Whole cell lysates of highly purified neutrophils were prepared in 1% Igepal CA-630 (Sigma Aldrich, St Quentin Fallavier, France), 40 mM Tris-HCl, pH 8, 150 mM NaCl, 5 mM EDTA, 5 mM iodoacetamide, 2 mM PMSF, and protease inhibitor mixture (Complete Mini tablet; Roche Applied Scienc, Sigma Aldrich, St Quentin Fallavier, France) at 4 &#x000b0;C for 30 min. The arginase activity level was determined using the Arginase Assay Kit according to the manufacturer&#x02019;s instructions (Sigma Aldrich, St Quentin Fallavier, France). The absorbance was measured at 450 nm using a Multiskan FC plate reader (ThermoFisher Scientific, Courtaboeuf, France).</p></sec><sec id="sec4dot12-cancers-12-01860"><title>4.12. TGF-&#x003b2; ELISA</title><p>Harvested tumors were immediately frozen in nitrogen liquid and thawed when cell lysates were prepared. A mechanical cell disruption and cell lysis was performed on a FastPrep-24 cell disruptor (MP Biomedical, Illkirch-Graffenstaden, France). Tumors were homogenized in 1% Igepal CA-630 (Sigma-Aldrich, St Quentin Fallavier, France), 10 mM Tris-HCl pH 8, 150mM NaCl, 5mM EDTA, 10% Glycerol, 0.5% anti-foam (silicone), and protease inhibitor mixture (Complete Mini tablet, Roche Applied Science, Sigma Aldrich, St Quentin Fallavier, France) and mixed with 0.5g Lysing Matrix D beads (MP Biomedicals Illkirch-Graffenstaden, France) before mechanical disruption. Supernatants were collected after centrifugation. Total protein quantification was performed using the BCA (bicinchoninic acid assay) protein assay (ThermoFisher Scientific, Courtaboeuf, France) and TGF-&#x003b2;1 concentrations determined by ELISA (Invitrogen, ThermoFisher Scientific, Courtaboeuf, France), according to the manufacturer&#x02019;s instructions.</p></sec><sec id="sec4dot13-cancers-12-01860"><title>4.13. Tumor Conditioned Medium and In Vitro Stimulation</title><p>Total tumor cells were cultured in complete DMEM medium supplemented with 10% FBS for 24 h. Cells were discarded by centrifugation and tumor-conditioned medium (TCM) was harvested and stored at &#x02212;20 &#x000b0;C. Aliquots of TCM were depleted of IFN-&#x003b3; by incubation of TCM with anti-IFN-&#x003b3; mAb (25 &#x003bc;g/mL) for 1 h at 4 &#x000b0;C followed by adsorption of the complex on Prot G-Sepharose 4B (Sigma-Aldrich, St Quentin Fallavier, France) for 30 min at 4 &#x000b0;C. Control aliquots of TCM were adsorbed on Protein G-Sephapose 4B alone. Treated TCM was collected by centrifugation and stored at &#x02212;20 &#x000b0;C. Highly purified BM was stimulated in vitro for 24 h with medium alone or in the presence of TCM (1/2) or 10 ng/mL IFN-&#x003b3;.</p></sec><sec id="sec4dot14-cancers-12-01860"><title>4.14. Statistical Analysis</title><p>Statistical analyses were carried out with Prism software version 6.0 (GraphPad Prism, San Diego, CA, USA). Depending on the data distribution (Shapiro normality test) and matched or not matched observations, a Kruskal&#x02013;Wallis one-way ANOVA, an unpaired <italic>t</italic> test, or a Mann&#x02013;Whitney test were used. Pairwise multiple comparisons of experimental groups were performed using two-way ANOVA. <italic>p</italic> &#x02264; 0.05 was considered statistically significant.</p></sec><sec id="sec4dot15-cancers-12-01860"><title>4.15. Data Deposition</title><p>The data reported in this article were deposited in the Gene Expression Omnibus (GEO) database, <uri xlink:href="https://www.ncbi.nlm.nih.gov/geo">https://www.ncbi.nlm.nih.gov/geo</uri> (accession nos. GSE133807).</p></sec></sec><sec sec-type="conclusions" id="sec5-cancers-12-01860"><title>5. Conclusions</title><p>In conclusion, this extensive in vivo study of TANs infiltrating cSCC underlines their diversity of functions and highlights their predominant involvement in immune suppression of CD8<sup>+</sup> T cell responses, notably through upregulation of PD-L1. It remains to broaden our knowledge of all the factors and cellular interactions in the TME that modulate the TAN&#x02019;s phenotype and functions. Targeting of TANs is a promising therapeutic strategy for the treatment of cSCC and other cancers highly infiltrated with protumor neutrophils.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank the IPMC&#x02019;s animal house, UCAGenomiX and Imaging/Flow cytometry core facilities, together with the MICA microscopy platform for providing assistance and Valentin Thomas for technical support. We thank Catherine Paul (EPHE, Dijon, France) and Antonio Sica (Humanitas Research Hospital, Milan, Italy) for critical review of this manuscript.</p></ack><app-group><app id="app1-cancers-12-01860"><title>Supplementary Materials</title><supplementary-material content-type="local-data" id="cancers-12-01860-s001"><media xlink:href="cancers-12-01860-s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><p>The following are available online at <uri xlink:href="https://www.mdpi.com/2072-6694/12/7/1860/s1">https://www.mdpi.com/2072-6694/12/7/1860/s1</uri>, Figure S1: Gene-expression analyses of cell-sorted neutrophils purified from skin and chemically-induced cSCC, Figure S2: IPA Canonical Pathway enrichments, Figure S3: Gene cluster GO-enrichment analyses, Figure S4: Common transcriptomic modulation signature between TANs in two different types of SCC, from the skin or the lung, Figure S5: Neutrophil frequencies and phenotypes in mSCC38-bearing mice, Figure S6: Analyses of tumor microenvironment of WT and neutrophil-depleted mice, Figure S7: Modulation of PD-L1 cell surface expression and survival of neutrophils.</p></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, S.K., A.P., C.L., F.B., F.A. and V.M.B.; Methodology, S.K., A.P., C.L., F.B., A.M.-K., P.B. (Pierre Bourdely), E.S., E.C., A.R., F.A. and V.M.B.; Validation, S.K., A.P., C.L., F.B., F.A. and V.M.B.; Formal analysis, S.K., A.P., C.L., F.B., A.M.-K., P.B. (Pierre Bourdely), F.A. and V.M.B.; Investigation, S.K., A.P., C.L., F.B., A.M.-K., P.B. (Pierre Bourdely), F.A. and V.M.B.; Resources, J.C., P.B. (Pascal Barbry), B.M. and R.R.; Data curation, J.C., P.B. (Pascal Barbry), B.M., R.R. and V.M.B.; Writing&#x02014;original draft preparation, S.K., A.P., F.A. and V.M.B.; Writing&#x02014;review and editing, V.M.B.; Visualization, V.M.B.; Supervision, F.A. and V.M.B.; Project administration, F.A. and V.M.B.; Funding acquisition, F.A. and V.M.B. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This research was funded by French National Agency, ANR through the &#x000ab; Investments for the Future &#x000bb; LABEX SIGNALIFE: ANR-11-LABX-0028-01; CANCEROPOLE PACA; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE; UNIVERSITE COTE D&#x02019;AZUR; REGION PROVENCE-ALPES- COTE D&#x02019;AZUR; FONDATION ARC pour la recherche sur le Cancer; FONDATION DE L&#x02019;AVENIR; LIGUE NATIONALE CONTRE LE CANCER; FONDATION D&#x02019;ENTREPRISE SILAB JEAN PAUFIQUE (C.L).</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.</p></notes><ref-list><title>References</title><ref id="B1-cancers-12-01860"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Didona</surname><given-names>D.</given-names></name><name><surname>Paolino</surname><given-names>G.</given-names></name><name><surname>Bottoni</surname><given-names>U.</given-names></name><name><surname>Cantisani</surname><given-names>C.</given-names></name></person-group><article-title>Non Melanoma Skin Cancer Pathogenesis Overview</article-title><source>Biomedicines</source><year>2018</year><volume>6</volume><elocation-id>6</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines6010006</pub-id><?supplied-pmid 29301290?><pub-id pub-id-type="pmid">29301290</pub-id></element-citation></ref><ref id="B2-cancers-12-01860"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Euvrard</surname><given-names>S.</given-names></name><name><surname>Kanitakis</surname><given-names>J.</given-names></name><name><surname>Claudy</surname><given-names>A.</given-names></name></person-group><article-title>Skin cancers after organ transplantation</article-title><source>N. Engl. J. Med.</source><year>2003</year><volume>348</volume><fpage>1681</fpage><lpage>1691</lpage><pub-id pub-id-type="doi">10.1056/NEJMra022137</pub-id><?supplied-pmid 12711744?><pub-id pub-id-type="pmid">12711744</pub-id></element-citation></ref><ref id="B3-cancers-12-01860"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>R.A.</given-names></name><name><surname>Huang</surname><given-names>S.J.</given-names></name><name><surname>Murphy</surname><given-names>G.F.</given-names></name><name><surname>Mollet</surname><given-names>I.G.</given-names></name><name><surname>Hijnen</surname><given-names>D.</given-names></name><name><surname>Muthukuru</surname><given-names>M.</given-names></name><name><surname>Schanbacher</surname><given-names>C.F.</given-names></name><name><surname>Edwards</surname><given-names>V.</given-names></name><name><surname>Miller</surname><given-names>D.M.</given-names></name><name><surname>Kim</surname><given-names>J.E.</given-names></name><etal/></person-group><article-title>Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells</article-title><source>J. Exp. Med.</source><year>2008</year><volume>205</volume><fpage>2221</fpage><lpage>2234</lpage><pub-id pub-id-type="doi">10.1084/jem.20071190</pub-id><?supplied-pmid 18794336?><pub-id pub-id-type="pmid">18794336</pub-id></element-citation></ref><ref id="B4-cancers-12-01860"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oppenheim</surname><given-names>D.E.</given-names></name><name><surname>Roberts</surname><given-names>S.J.</given-names></name><name><surname>Clarke</surname><given-names>S.L.</given-names></name><name><surname>Filler</surname><given-names>R.</given-names></name><name><surname>Lewis</surname><given-names>J.M.</given-names></name><name><surname>Tigelaar</surname><given-names>R.E.</given-names></name><name><surname>Girardi</surname><given-names>M.</given-names></name><name><surname>Hayday</surname><given-names>A.C.</given-names></name></person-group><article-title>Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance</article-title><source>Nat. Immunol.</source><year>2005</year><volume>6</volume><fpage>928</fpage><lpage>937</lpage><pub-id pub-id-type="doi">10.1038/ni1239</pub-id><?supplied-pmid 16116470?><pub-id pub-id-type="pmid">16116470</pub-id></element-citation></ref><ref id="B5-cancers-12-01860"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamieson</surname><given-names>T.</given-names></name><name><surname>Clarke</surname><given-names>M.</given-names></name><name><surname>Steele</surname><given-names>C.W.</given-names></name><name><surname>Samuel</surname><given-names>M.S.</given-names></name><name><surname>Neumann</surname><given-names>J.</given-names></name><name><surname>Jung</surname><given-names>A.</given-names></name><name><surname>Huels</surname><given-names>D.</given-names></name><name><surname>Olson</surname><given-names>M.F.</given-names></name><name><surname>Das</surname><given-names>S.</given-names></name><name><surname>Nibbs</surname><given-names>R.J.</given-names></name><etal/></person-group><article-title>Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis</article-title><source>J. Clin. Invest.</source><year>2012</year><volume>122</volume><fpage>3127</fpage><lpage>3144</lpage><pub-id pub-id-type="doi">10.1172/JCI61067</pub-id><pub-id pub-id-type="pmid">22922255</pub-id></element-citation></ref><ref id="B6-cancers-12-01860"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seddon</surname><given-names>A.</given-names></name><name><surname>Hock</surname><given-names>B.</given-names></name><name><surname>Miller</surname><given-names>A.</given-names></name><name><surname>Frei</surname><given-names>L.</given-names></name><name><surname>Pearson</surname><given-names>J.</given-names></name><name><surname>McKenzie</surname><given-names>J.</given-names></name><name><surname>Simcock</surname><given-names>J.</given-names></name><name><surname>Currie</surname><given-names>M.</given-names></name></person-group><article-title>Cutaneous squamous cell carcinomas with markers of increased metastatic risk are associated with elevated numbers of neutrophils and/or granulocytic myeloid derived suppressor cells</article-title><source>J. Dermatol. Sci.</source><year>2016</year><volume>83</volume><fpage>124</fpage><lpage>130</lpage><pub-id pub-id-type="doi">10.1016/j.jdermsci.2016.04.013</pub-id><?supplied-pmid 27160951?><pub-id pub-id-type="pmid">27160951</pub-id></element-citation></ref><ref id="B7-cancers-12-01860"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>O&#x02019;Leary</surname><given-names>C.E.</given-names></name><name><surname>Wang</surname><given-names>L.S.</given-names></name><name><surname>Bhatti</surname><given-names>T.R.</given-names></name><name><surname>Dai</surname><given-names>N.</given-names></name><name><surname>Kapoor</surname><given-names>V.</given-names></name><name><surname>Liu</surname><given-names>P.</given-names></name><name><surname>Mei</surname><given-names>J.</given-names></name><name><surname>Guo</surname><given-names>L.</given-names></name><name><surname>Oliver</surname><given-names>P.M.</given-names></name><etal/></person-group><article-title>CD11b+Ly6G+ cells inhibit tumor growth by suppressing IL-17 production at early stages of tumorigenesis</article-title><source>Oncoimmunology</source><year>2016</year><volume>5</volume><fpage>e1061175</fpage><pub-id pub-id-type="doi">10.1080/2162402X.2015.1061175</pub-id><?supplied-pmid 26942073?><pub-id pub-id-type="pmid">26942073</pub-id></element-citation></ref><ref id="B8-cancers-12-01860"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ponzetta</surname><given-names>A.</given-names></name><name><surname>Carriero</surname><given-names>R.</given-names></name><name><surname>Carnevale</surname><given-names>S.</given-names></name><name><surname>Barbagallo</surname><given-names>M.</given-names></name><name><surname>Molgora</surname><given-names>M.</given-names></name><name><surname>Perucchini</surname><given-names>C.</given-names></name><name><surname>Magrini</surname><given-names>E.</given-names></name><name><surname>Gianni</surname><given-names>F.</given-names></name><name><surname>Kunderfranco</surname><given-names>P.</given-names></name><name><surname>Polentarutti</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Neutrophils Driving Unconventional T Cells Mediate Resistance against Murine Sarcomas and Selected Human Tumors</article-title><source>Cell</source><year>2019</year><volume>178</volume><fpage>346</fpage><lpage>360</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.05.047</pub-id><pub-id pub-id-type="pmid">31257026</pub-id></element-citation></ref><ref id="B9-cancers-12-01860"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fridlender</surname><given-names>Z.G.</given-names></name><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Kapoor</surname><given-names>V.</given-names></name><name><surname>Cheng</surname><given-names>G.</given-names></name><name><surname>Ling</surname><given-names>L.</given-names></name><name><surname>Worthen</surname><given-names>G.S.</given-names></name><name><surname>Albelda</surname><given-names>S.M.</given-names></name></person-group><article-title>Polarization of tumor-associated neutrophil phenotype by TGF-beta: &#x0201c;N1&#x0201d; versus &#x0201c;N2&#x0201d; TAN</article-title><source>Cancer Cell</source><year>2009</year><volume>16</volume><fpage>183</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2009.06.017</pub-id><pub-id pub-id-type="pmid">19732719</pub-id></element-citation></ref><ref id="B10-cancers-12-01860"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Nefedova</surname><given-names>Y.</given-names></name><name><surname>Lei</surname><given-names>A.</given-names></name><name><surname>Gabrilovich</surname><given-names>D.</given-names></name></person-group><article-title>Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells</article-title><source>Semin. Immunol.</source><year>2018</year><volume>35</volume><fpage>19</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.smim.2017.12.004</pub-id><?supplied-pmid 29254756?><pub-id pub-id-type="pmid">29254756</pub-id></element-citation></ref><ref id="B11-cancers-12-01860"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coffelt</surname><given-names>S.B.</given-names></name><name><surname>Wellenstein</surname><given-names>M.D.</given-names></name><name><surname>de Visser</surname><given-names>K.E.</given-names></name></person-group><article-title>Neutrophils in cancer: Neutral no more</article-title><source>Nat. Rev. Cancer</source><year>2016</year><volume>16</volume><fpage>431</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1038/nrc.2016.52</pub-id><?supplied-pmid 27282249?><pub-id pub-id-type="pmid">27282249</pub-id></element-citation></ref><ref id="B12-cancers-12-01860"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandau</surname><given-names>S.</given-names></name></person-group><article-title>The dichotomy of neutrophil granulocytes in cancer</article-title><source>Semin. Cancer Biol.</source><year>2013</year><volume>23</volume><fpage>139</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2013.02.008</pub-id><?supplied-pmid 23454237?><pub-id pub-id-type="pmid">23454237</pub-id></element-citation></ref><ref id="B13-cancers-12-01860"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andzinski</surname><given-names>L.</given-names></name><name><surname>Kasnitz</surname><given-names>N.</given-names></name><name><surname>Stahnke</surname><given-names>S.</given-names></name><name><surname>Wu</surname><given-names>C.F.</given-names></name><name><surname>Gereke</surname><given-names>M.</given-names></name><name><surname>von Kockritz-Blickwede</surname><given-names>M.</given-names></name><name><surname>Schilling</surname><given-names>B.</given-names></name><name><surname>Brandau</surname><given-names>S.</given-names></name><name><surname>Weiss</surname><given-names>S.</given-names></name><name><surname>Jablonska</surname><given-names>J.</given-names></name></person-group><article-title>Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human</article-title><source>Int. J. Cancer</source><year>2016</year><volume>138</volume><fpage>1982</fpage><lpage>1993</lpage><pub-id pub-id-type="doi">10.1002/ijc.29945</pub-id><?supplied-pmid 26619320?><pub-id pub-id-type="pmid">26619320</pub-id></element-citation></ref><ref id="B14-cancers-12-01860"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gentles</surname><given-names>A.J.</given-names></name><name><surname>Newman</surname><given-names>A.M.</given-names></name><name><surname>Liu</surname><given-names>C.L.</given-names></name><name><surname>Bratman</surname><given-names>S.V.</given-names></name><name><surname>Feng</surname><given-names>W.</given-names></name><name><surname>Kim</surname><given-names>D.</given-names></name><name><surname>Nair</surname><given-names>V.S.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Khuong</surname><given-names>A.</given-names></name><name><surname>Hoang</surname><given-names>C.D.</given-names></name><etal/></person-group><article-title>The prognostic landscape of genes and infiltrating immune cells across human cancers</article-title><source>Nat. Med.</source><year>2015</year><volume>21</volume><fpage>938</fpage><lpage>945</lpage><pub-id pub-id-type="doi">10.1038/nm.3909</pub-id><?supplied-pmid 26193342?><pub-id pub-id-type="pmid">26193342</pub-id></element-citation></ref><ref id="B15-cancers-12-01860"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Templeton</surname><given-names>A.J.</given-names></name><name><surname>McNamara</surname><given-names>M.G.</given-names></name><name><surname>Seruga</surname><given-names>B.</given-names></name><name><surname>Vera-Badillo</surname><given-names>F.E.</given-names></name><name><surname>Aneja</surname><given-names>P.</given-names></name><name><surname>Ocana</surname><given-names>A.</given-names></name><name><surname>Leibowitz-Amit</surname><given-names>R.</given-names></name><name><surname>Sonpavde</surname><given-names>G.</given-names></name><name><surname>Knox</surname><given-names>J.J.</given-names></name><name><surname>Tran</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis</article-title><source>J. Natl. Cancer Inst.</source><year>2014</year><volume>106</volume><pub-id pub-id-type="doi">10.1093/jnci/dju124</pub-id><?supplied-pmid 24875653?><pub-id pub-id-type="pmid">24875653</pub-id></element-citation></ref><ref id="B16-cancers-12-01860"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gabrilovich</surname><given-names>D.I.</given-names></name><name><surname>Nagaraj</surname><given-names>S.</given-names></name></person-group><article-title>Myeloid-derived suppressor cells as regulators of the immune system</article-title><source>Nat. Rev. Immunol</source><year>2009</year><volume>9</volume><fpage>162</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1038/nri2506</pub-id><pub-id pub-id-type="pmid">19197294</pub-id></element-citation></ref><ref id="B17-cancers-12-01860"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandau</surname><given-names>S.</given-names></name><name><surname>Dumitru</surname><given-names>C.A.</given-names></name><name><surname>Lang</surname><given-names>S.</given-names></name></person-group><article-title>Protumor and antitumor functions of neutrophil granulocytes</article-title><source>Semin. Immunopathol.</source><year>2013</year><volume>35</volume><fpage>163</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1007/s00281-012-0344-6</pub-id><pub-id pub-id-type="pmid">23007469</pub-id></element-citation></ref><ref id="B18-cancers-12-01860"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zilionis</surname><given-names>R.</given-names></name><name><surname>Engblom</surname><given-names>C.</given-names></name><name><surname>Pfirschke</surname><given-names>C.</given-names></name><name><surname>Savova</surname><given-names>V.</given-names></name><name><surname>Zemmour</surname><given-names>D.</given-names></name><name><surname>Saatcioglu</surname><given-names>H.D.</given-names></name><name><surname>Krishnan</surname><given-names>I.</given-names></name><name><surname>Maroni</surname><given-names>G.</given-names></name><name><surname>Meyerovitz</surname><given-names>C.V.</given-names></name><name><surname>Kerwin</surname><given-names>C.M.</given-names></name><etal/></person-group><article-title>Single-Cell Transcriptomics of Human and Mouse Lung Cancers Reveals Conserved Myeloid Populations across Individuals and Species</article-title><source>Immunity</source><year>2019</year><volume>50</volume><fpage>1317</fpage><lpage>1334.e1310</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2019.03.009</pub-id><?supplied-pmid 30979687?><pub-id pub-id-type="pmid">30979687</pub-id></element-citation></ref><ref id="B19-cancers-12-01860"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fridlender</surname><given-names>Z.G.</given-names></name><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>Mishalian</surname><given-names>I.</given-names></name><name><surname>Singhal</surname><given-names>S.</given-names></name><name><surname>Cheng</surname><given-names>G.</given-names></name><name><surname>Kapoor</surname><given-names>V.</given-names></name><name><surname>Horng</surname><given-names>W.</given-names></name><name><surname>Fridlender</surname><given-names>G.</given-names></name><name><surname>Bayuh</surname><given-names>R.</given-names></name><name><surname>Worthen</surname><given-names>G.S.</given-names></name><etal/></person-group><article-title>Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils</article-title><source>PLos ONE</source><year>2012</year><volume>7</volume><elocation-id>e31524</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0031524</pub-id><?supplied-pmid 22348096?><pub-id pub-id-type="pmid">22348096</pub-id></element-citation></ref><ref id="B20-cancers-12-01860"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Youn</surname><given-names>J.I.</given-names></name><name><surname>Collazo</surname><given-names>M.</given-names></name><name><surname>Shalova</surname><given-names>I.N.</given-names></name><name><surname>Biswas</surname><given-names>S.K.</given-names></name><name><surname>Gabrilovich</surname><given-names>D.I.</given-names></name></person-group><article-title>Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice</article-title><source>J. Leukoc. Biol.</source><year>2012</year><volume>91</volume><fpage>167</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1189/jlb.0311177</pub-id><pub-id pub-id-type="pmid">21954284</pub-id></element-citation></ref><ref id="B21-cancers-12-01860"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lakschevitz</surname><given-names>F.S.</given-names></name><name><surname>Visser</surname><given-names>M.B.</given-names></name><name><surname>Sun</surname><given-names>C.</given-names></name><name><surname>Glogauer</surname><given-names>M.</given-names></name></person-group><article-title>Neutrophil transcriptional profile changes during transit from bone marrow to sites of inflammation</article-title><source>Cell Mol. Immunol.</source><year>2015</year><volume>12</volume><fpage>53</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1038/cmi.2014.37</pub-id><?supplied-pmid 24909740?><pub-id pub-id-type="pmid">24909740</pub-id></element-citation></ref><ref id="B22-cancers-12-01860"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owens</surname><given-names>D.M.</given-names></name><name><surname>Wei</surname><given-names>S.</given-names></name><name><surname>Smart</surname><given-names>R.C.</given-names></name></person-group><article-title>A multihit, multistage model of chemical carcinogenesis</article-title><source>Carcinogenesis</source><year>1999</year><volume>20</volume><fpage>1837</fpage><lpage>1844</lpage><pub-id pub-id-type="doi">10.1093/carcin/20.9.1837</pub-id><?supplied-pmid 10469632?><pub-id pub-id-type="pmid">10469632</pub-id></element-citation></ref><ref id="B23-cancers-12-01860"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gastaldi</surname><given-names>C.</given-names></name><name><surname>Bertero</surname><given-names>T.</given-names></name><name><surname>Xu</surname><given-names>N.</given-names></name><name><surname>Bourget-Ponzio</surname><given-names>I.</given-names></name><name><surname>Lebrigand</surname><given-names>K.</given-names></name><name><surname>Fourre</surname><given-names>S.</given-names></name><name><surname>Popa</surname><given-names>A.</given-names></name><name><surname>Cardot-Leccia</surname><given-names>N.</given-names></name><name><surname>Meneguzzi</surname><given-names>G.</given-names></name><name><surname>Sonkoly</surname><given-names>E.</given-names></name><etal/></person-group><article-title>miR-193b/365a cluster controls progression of epidermal squamous cell carcinoma</article-title><source>Carcinogenesis</source><year>2014</year><volume>35</volume><fpage>1110</fpage><lpage>1120</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgt490</pub-id><?supplied-pmid 24374827?><pub-id pub-id-type="pmid">24374827</pub-id></element-citation></ref><ref id="B24-cancers-12-01860"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abel</surname><given-names>E.L.</given-names></name><name><surname>Angel</surname><given-names>J.M.</given-names></name><name><surname>Kiguchi</surname><given-names>K.</given-names></name><name><surname>DiGiovanni</surname><given-names>J.</given-names></name></person-group><article-title>Multi-stage chemical carcinogenesis in mouse skin: Fundamentals and applications</article-title><source>Nat. Protoc.</source><year>2009</year><volume>4</volume><fpage>1350</fpage><lpage>1362</lpage><pub-id pub-id-type="doi">10.1038/nprot.2009.120</pub-id><?supplied-pmid 19713956?><pub-id pub-id-type="pmid">19713956</pub-id></element-citation></ref><ref id="B25-cancers-12-01860"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daley</surname><given-names>J.M.</given-names></name><name><surname>Thomay</surname><given-names>A.A.</given-names></name><name><surname>Connolly</surname><given-names>M.D.</given-names></name><name><surname>Reichner</surname><given-names>J.S.</given-names></name><name><surname>Albina</surname><given-names>J.E.</given-names></name></person-group><article-title>Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice</article-title><source>J. Leukoc. Biol.</source><year>2008</year><volume>83</volume><fpage>64</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1189/jlb.0407247</pub-id><?supplied-pmid 17884993?><pub-id pub-id-type="pmid">17884993</pub-id></element-citation></ref><ref id="B26-cancers-12-01860"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>B.P.</given-names></name><name><surname>Rothenberg</surname><given-names>M.E.</given-names></name></person-group><article-title>Eosinophils and cancer</article-title><source>Cancer Immunol. Res.</source><year>2014</year><volume>2</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-13-0196</pub-id><pub-id pub-id-type="pmid">24778159</pub-id></element-citation></ref><ref id="B27-cancers-12-01860"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glodde</surname><given-names>N.</given-names></name><name><surname>Bald</surname><given-names>T.</given-names></name><name><surname>van den Boorn-Konijnenberg</surname><given-names>D.</given-names></name><name><surname>Nakamura</surname><given-names>K.</given-names></name><name><surname>O&#x02019;Donnell</surname><given-names>J.S.</given-names></name><name><surname>Szczepanski</surname><given-names>S.</given-names></name><name><surname>Brandes</surname><given-names>M.</given-names></name><name><surname>Eickhoff</surname><given-names>S.</given-names></name><name><surname>Das</surname><given-names>I.</given-names></name><name><surname>Shridhar</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy</article-title><source>Immunity</source><year>2017</year><volume>47</volume><fpage>789</fpage><lpage>802.e789</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.09.012</pub-id><?supplied-pmid 29045907?><pub-id pub-id-type="pmid">29045907</pub-id></element-citation></ref><ref id="B28-cancers-12-01860"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Kleijn</surname><given-names>S.</given-names></name><name><surname>Langereis</surname><given-names>J.D.</given-names></name><name><surname>Leentjens</surname><given-names>J.</given-names></name><name><surname>Kox</surname><given-names>M.</given-names></name><name><surname>Netea</surname><given-names>M.G.</given-names></name><name><surname>Koenderman</surname><given-names>L.</given-names></name><name><surname>Ferwerda</surname><given-names>G.</given-names></name><name><surname>Pickkers</surname><given-names>P.</given-names></name><name><surname>Hermans</surname><given-names>P.W.</given-names></name></person-group><article-title>IFN-gamma-stimulated neutrophils suppress lymphocyte proliferation through expression of PD-L1</article-title><source>PLos ONE</source><year>2013</year><volume>8</volume><elocation-id>e72249</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0072249</pub-id><pub-id pub-id-type="pmid">24015224</pub-id></element-citation></ref><ref id="B29-cancers-12-01860"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goncalves-Maia</surname><given-names>M.</given-names></name><name><surname>Gache</surname><given-names>Y.</given-names></name><name><surname>Basante</surname><given-names>M.</given-names></name><name><surname>Cosson</surname><given-names>E.</given-names></name><name><surname>Salavagione</surname><given-names>E.</given-names></name><name><surname>Muller</surname><given-names>M.</given-names></name><name><surname>Bernerd</surname><given-names>F.</given-names></name><name><surname>Avril</surname><given-names>M.F.</given-names></name><name><surname>Schaub</surname><given-names>S.</given-names></name><name><surname>Sarasin</surname><given-names>A.</given-names></name><etal/></person-group><article-title>NK Cell and Fibroblast-Mediated Regulation of Skin Squamous Cell Carcinoma Invasion by CLEC2A Is Compromised in Xeroderma Pigmentosum</article-title><source>J. Invest. Dermatol.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.jid.2020.01.021</pub-id></element-citation></ref><ref id="B30-cancers-12-01860"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moses</surname><given-names>K.</given-names></name><name><surname>Brandau</surname><given-names>S.</given-names></name></person-group><article-title>Human neutrophils: Their role in cancer and relation to myeloid-derived suppressor cells</article-title><source>Semin. Immunol.</source><year>2016</year><volume>28</volume><fpage>187</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1016/j.smim.2016.03.018</pub-id><pub-id pub-id-type="pmid">27067179</pub-id></element-citation></ref><ref id="B31-cancers-12-01860"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veglia</surname><given-names>F.</given-names></name><name><surname>Perego</surname><given-names>M.</given-names></name><name><surname>Gabrilovich</surname><given-names>D.</given-names></name></person-group><article-title>Myeloid-derived suppressor cells coming of age</article-title><source>Nat. Immunol.</source><year>2018</year><volume>19</volume><fpage>108</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1038/s41590-017-0022-x</pub-id><?supplied-pmid 29348500?><pub-id pub-id-type="pmid">29348500</pub-id></element-citation></ref><ref id="B32-cancers-12-01860"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engblom</surname><given-names>C.</given-names></name><name><surname>Pfirschke</surname><given-names>C.</given-names></name><name><surname>Zilionis</surname><given-names>R.</given-names></name><name><surname>Da Silva Martins</surname><given-names>J.</given-names></name><name><surname>Bos</surname><given-names>S.A.</given-names></name><name><surname>Courties</surname><given-names>G.</given-names></name><name><surname>Rickelt</surname><given-names>S.</given-names></name><name><surname>Severe</surname><given-names>N.</given-names></name><name><surname>Baryawno</surname><given-names>N.</given-names></name><name><surname>Faget</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Osteoblasts remotely supply lung tumors with cancer-promoting SiglecF(high) neutrophils</article-title><source>Science</source><year>2017</year><volume>358</volume><pub-id pub-id-type="doi">10.1126/science.aal5081</pub-id><?supplied-pmid 29191879?><pub-id pub-id-type="pmid">29191879</pub-id></element-citation></ref><ref id="B33-cancers-12-01860"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Condamine</surname><given-names>T.</given-names></name><name><surname>Dominguez</surname><given-names>G.A.</given-names></name><name><surname>Youn</surname><given-names>J.I.</given-names></name><name><surname>Kossenkov</surname><given-names>A.V.</given-names></name><name><surname>Mony</surname><given-names>S.</given-names></name><name><surname>Alicea-Torres</surname><given-names>K.</given-names></name><name><surname>Tcyganov</surname><given-names>E.</given-names></name><name><surname>Hashimoto</surname><given-names>A.</given-names></name><name><surname>Nefedova</surname><given-names>Y.</given-names></name><name><surname>Lin</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients</article-title><source>Sci. Immunol.</source><year>2016</year><volume>1</volume><pub-id pub-id-type="doi">10.1126/sciimmunol.aaf8943</pub-id></element-citation></ref><ref id="B34-cancers-12-01860"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>G.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Kong</surname><given-names>Y.</given-names></name><name><surname>Xie</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Fei</surname><given-names>R.</given-names></name><name><surname>Wei</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma</article-title><source>J. Exp. Clin. Cancer Res.</source><year>2015</year><volume>34</volume><fpage>141</fpage><pub-id pub-id-type="doi">10.1186/s13046-015-0256-0</pub-id><pub-id pub-id-type="pmid">26581194</pub-id></element-citation></ref><ref id="B35-cancers-12-01860"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mollaoglu</surname><given-names>G.</given-names></name><name><surname>Jones</surname><given-names>A.</given-names></name><name><surname>Wait</surname><given-names>S.J.</given-names></name><name><surname>Mukhopadhyay</surname><given-names>A.</given-names></name><name><surname>Jeong</surname><given-names>S.</given-names></name><name><surname>Arya</surname><given-names>R.</given-names></name><name><surname>Camolotto</surname><given-names>S.A.</given-names></name><name><surname>Mosbruger</surname><given-names>T.L.</given-names></name><name><surname>Stubben</surname><given-names>C.J.</given-names></name><name><surname>Conley</surname><given-names>C.J.</given-names></name><etal/></person-group><article-title>The Lineage-Defining Transcription Factors SOX2 and NKX2-1 Determine Lung Cancer Cell Fate and Shape the Tumor Immune Microenvironment</article-title><source>Immunity</source><year>2018</year><volume>49</volume><fpage>764</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2018.09.020</pub-id><pub-id pub-id-type="pmid">30332632</pub-id></element-citation></ref><ref id="B36-cancers-12-01860"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gregory</surname><given-names>A.D.</given-names></name><name><surname>Houghton</surname><given-names>A.M.</given-names></name></person-group><article-title>Tumor-associated neutrophils: New targets for cancer therapy</article-title><source>Cancer Res.</source><year>2011</year><volume>71</volume><fpage>2411</fpage><lpage>2416</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-2583</pub-id><pub-id pub-id-type="pmid">21427354</pub-id></element-citation></ref><ref id="B37-cancers-12-01860"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raber</surname><given-names>P.L.</given-names></name><name><surname>Thevenot</surname><given-names>P.</given-names></name><name><surname>Sierra</surname><given-names>R.</given-names></name><name><surname>Wyczechowska</surname><given-names>D.</given-names></name><name><surname>Halle</surname><given-names>D.</given-names></name><name><surname>Ramirez</surname><given-names>M.E.</given-names></name><name><surname>Ochoa</surname><given-names>A.C.</given-names></name><name><surname>Fletcher</surname><given-names>M.</given-names></name><name><surname>Velasco</surname><given-names>C.</given-names></name><name><surname>Wilk</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways</article-title><source>Int. J. Cancer</source><year>2014</year><volume>134</volume><fpage>2853</fpage><lpage>2864</lpage><pub-id pub-id-type="doi">10.1002/ijc.28622</pub-id><pub-id pub-id-type="pmid">24259296</pub-id></element-citation></ref><ref id="B38-cancers-12-01860"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Negorev</surname><given-names>D.</given-names></name><name><surname>Beier</surname><given-names>U.H.</given-names></name><name><surname>Zhang</surname><given-names>T.</given-names></name><name><surname>Quatromoni</surname><given-names>J.G.</given-names></name><name><surname>Bhojnagarwala</surname><given-names>P.</given-names></name><name><surname>Albelda</surname><given-names>S.M.</given-names></name><name><surname>Singhal</surname><given-names>S.</given-names></name><name><surname>Eruslanov</surname><given-names>E.</given-names></name><name><surname>Lohoff</surname><given-names>F.W.</given-names></name><name><surname>Levine</surname><given-names>M.H.</given-names></name><etal/></person-group><article-title>Human neutrophils can mimic myeloid-derived suppressor cells (PMN-MDSC) and suppress microbead or lectin-induced T cell proliferation through artefactual mechanisms</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>3135</fpage><pub-id pub-id-type="doi">10.1038/s41598-018-21450-6</pub-id><pub-id pub-id-type="pmid">29453429</pub-id></element-citation></ref><ref id="B39-cancers-12-01860"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T.T.</given-names></name><name><surname>Zhao</surname><given-names>Y.L.</given-names></name><name><surname>Peng</surname><given-names>L.S.</given-names></name><name><surname>Chen</surname><given-names>N.</given-names></name><name><surname>Chen</surname><given-names>W.</given-names></name><name><surname>Lv</surname><given-names>Y.P.</given-names></name><name><surname>Mao</surname><given-names>F.Y.</given-names></name><name><surname>Zhang</surname><given-names>J.Y.</given-names></name><name><surname>Cheng</surname><given-names>P.</given-names></name><name><surname>Teng</surname><given-names>Y.S.</given-names></name><etal/></person-group><article-title>Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway</article-title><source>Gut</source><year>2017</year><volume>66</volume><fpage>1900</fpage><lpage>1911</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2016-313075</pub-id><pub-id pub-id-type="pmid">28274999</pub-id></element-citation></ref><ref id="B40-cancers-12-01860"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eruslanov</surname><given-names>E.B.</given-names></name><name><surname>Bhojnagarwala</surname><given-names>P.S.</given-names></name><name><surname>Quatromoni</surname><given-names>J.G.</given-names></name><name><surname>Stephen</surname><given-names>T.L.</given-names></name><name><surname>Ranganathan</surname><given-names>A.</given-names></name><name><surname>Deshpande</surname><given-names>C.</given-names></name><name><surname>Akimova</surname><given-names>T.</given-names></name><name><surname>Vachani</surname><given-names>A.</given-names></name><name><surname>Litzky</surname><given-names>L.</given-names></name><name><surname>Hancock</surname><given-names>W.W.</given-names></name><etal/></person-group><article-title>Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer</article-title><source>J. Clin. Invest.</source><year>2014</year><volume>124</volume><fpage>5466</fpage><lpage>5480</lpage><pub-id pub-id-type="doi">10.1172/JCI77053</pub-id><pub-id pub-id-type="pmid">25384214</pub-id></element-citation></ref><ref id="B41-cancers-12-01860"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kargl</surname><given-names>J.</given-names></name><name><surname>Busch</surname><given-names>S.E.</given-names></name><name><surname>Yang</surname><given-names>G.H.</given-names></name><name><surname>Kim</surname><given-names>K.H.</given-names></name><name><surname>Hanke</surname><given-names>M.L.</given-names></name><name><surname>Metz</surname><given-names>H.E.</given-names></name><name><surname>Hubbard</surname><given-names>J.J.</given-names></name><name><surname>Lee</surname><given-names>S.M.</given-names></name><name><surname>Madtes</surname><given-names>D.K.</given-names></name><name><surname>McIntosh</surname><given-names>M.W.</given-names></name><etal/></person-group><article-title>Neutrophils dominate the immune cell composition in non-small cell lung cancer</article-title><source>Nat. Commun.</source><year>2017</year><volume>8</volume><fpage>14381</fpage><pub-id pub-id-type="doi">10.1038/ncomms14381</pub-id><?supplied-pmid 28146145?><pub-id pub-id-type="pmid">28146145</pub-id></element-citation></ref><ref id="B42-cancers-12-01860"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>V.</given-names></name><name><surname>Patel</surname><given-names>S.</given-names></name><name><surname>Tcyganov</surname><given-names>E.</given-names></name><name><surname>Gabrilovich</surname><given-names>D.I.</given-names></name></person-group><article-title>The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment</article-title><source>Trends Immunol.</source><year>2016</year><volume>37</volume><fpage>208</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1016/j.it.2016.01.004</pub-id><?supplied-pmid 26858199?><pub-id pub-id-type="pmid">26858199</pub-id></element-citation></ref><ref id="B43-cancers-12-01860"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elpek</surname><given-names>K.G.</given-names></name><name><surname>Cremasco</surname><given-names>V.</given-names></name><name><surname>Shen</surname><given-names>H.</given-names></name><name><surname>Harvey</surname><given-names>C.J.</given-names></name><name><surname>Wucherpfennig</surname><given-names>K.W.</given-names></name><name><surname>Goldstein</surname><given-names>D.R.</given-names></name><name><surname>Monach</surname><given-names>P.A.</given-names></name><name><surname>Turley</surname><given-names>S.J.</given-names></name></person-group><article-title>The tumor microenvironment shapes lineage, transcriptional, and functional diversity of infiltrating myeloid cells</article-title><source>Cancer Immunol. Res.</source><year>2014</year><volume>2</volume><fpage>655</fpage><lpage>667</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-13-0209</pub-id><?supplied-pmid 24801837?><pub-id pub-id-type="pmid">24801837</pub-id></element-citation></ref><ref id="B44-cancers-12-01860"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sagiv</surname><given-names>J.Y.</given-names></name><name><surname>Michaeli</surname><given-names>J.</given-names></name><name><surname>Assi</surname><given-names>S.</given-names></name><name><surname>Mishalian</surname><given-names>I.</given-names></name><name><surname>Kisos</surname><given-names>H.</given-names></name><name><surname>Levy</surname><given-names>L.</given-names></name><name><surname>Damti</surname><given-names>P.</given-names></name><name><surname>Lumbroso</surname><given-names>D.</given-names></name><name><surname>Polyansky</surname><given-names>L.</given-names></name><name><surname>Sionov</surname><given-names>R.V.</given-names></name><etal/></person-group><article-title>Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer</article-title><source>Cell Rep.</source><year>2015</year><volume>10</volume><fpage>562</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2014.12.039</pub-id><?supplied-pmid 25620698?><pub-id pub-id-type="pmid">25620698</pub-id></element-citation></ref><ref id="B45-cancers-12-01860"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singhal</surname><given-names>S.</given-names></name><name><surname>Bhojnagarwala</surname><given-names>P.S.</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>S.</given-names></name><name><surname>Moon</surname><given-names>E.K.</given-names></name><name><surname>Garfall</surname><given-names>A.L.</given-names></name><name><surname>Rao</surname><given-names>A.S.</given-names></name><name><surname>Quatromoni</surname><given-names>J.G.</given-names></name><name><surname>Stephen</surname><given-names>T.L.</given-names></name><name><surname>Litzky</surname><given-names>L.</given-names></name><name><surname>Deshpande</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer</article-title><source>Cancer Cell</source><year>2016</year><volume>30</volume><fpage>120</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2016.06.001</pub-id><?supplied-pmid 27374224?><pub-id pub-id-type="pmid">27374224</pub-id></element-citation></ref><ref id="B46-cancers-12-01860"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>A.</given-names></name><name><surname>Seignez</surname><given-names>C.</given-names></name><name><surname>Racoeur</surname><given-names>C.</given-names></name><name><surname>Isambert</surname><given-names>N.</given-names></name><name><surname>Mabrouk</surname><given-names>N.</given-names></name><name><surname>Scagliarini</surname><given-names>A.</given-names></name><name><surname>Reveneau</surname><given-names>S.</given-names></name><name><surname>Arnould</surname><given-names>L.</given-names></name><name><surname>Bettaieb</surname><given-names>A.</given-names></name><name><surname>Jeannin</surname><given-names>J.F.</given-names></name><etal/></person-group><article-title>Tumor-derived granzyme B-expressing neutrophils acquire antitumor potential after lipid A treatment</article-title><source>Oncotarget</source><year>2018</year><volume>9</volume><fpage>28364</fpage><lpage>28378</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.25342</pub-id><pub-id pub-id-type="pmid">29983866</pub-id></element-citation></ref><ref id="B47-cancers-12-01860"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finisguerra</surname><given-names>V.</given-names></name><name><surname>Di Conza</surname><given-names>G.</given-names></name><name><surname>Di Matteo</surname><given-names>M.</given-names></name><name><surname>Serneels</surname><given-names>J.</given-names></name><name><surname>Costa</surname><given-names>S.</given-names></name><name><surname>Thompson</surname><given-names>A.A.</given-names></name><name><surname>Wauters</surname><given-names>E.</given-names></name><name><surname>Walmsley</surname><given-names>S.</given-names></name><name><surname>Prenen</surname><given-names>H.</given-names></name><name><surname>Granot</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>MET is required for the recruitment of anti-tumoural neutrophils</article-title><source>Nature</source><year>2015</year><volume>522</volume><fpage>349</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1038/nature14407</pub-id><?supplied-pmid 25985180?><pub-id pub-id-type="pmid">25985180</pub-id></element-citation></ref><ref id="B48-cancers-12-01860"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vannini</surname><given-names>F.</given-names></name><name><surname>Kashfi</surname><given-names>K.</given-names></name><name><surname>Nath</surname><given-names>N.</given-names></name></person-group><article-title>The dual role of iNOS in cancer</article-title><source>Redox Biol.</source><year>2015</year><volume>6</volume><fpage>334</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1016/j.redox.2015.08.009</pub-id><pub-id pub-id-type="pmid">26335399</pub-id></element-citation></ref><ref id="B49-cancers-12-01860"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fortunati</surname><given-names>E.</given-names></name><name><surname>Kazemier</surname><given-names>K.M.</given-names></name><name><surname>Grutters</surname><given-names>J.C.</given-names></name><name><surname>Koenderman</surname><given-names>L.</given-names></name><name><surname>Van den Bosch v</surname><given-names>J.</given-names></name></person-group><article-title>Human neutrophils switch to an activated phenotype after homing to the lung irrespective of inflammatory disease</article-title><source>Clin. Exp. Immunol.</source><year>2009</year><volume>155</volume><fpage>559</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2249.2008.03791.x</pub-id><pub-id pub-id-type="pmid">19077082</pub-id></element-citation></ref><ref id="B50-cancers-12-01860"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Cai</surname><given-names>Y.</given-names></name><name><surname>Fu</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>N.</given-names></name><name><surname>Fu</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name></person-group><article-title>IFN-gamma-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling</article-title><source>Int. J. Cancer</source><year>2018</year><volume>143</volume><fpage>931</fpage><lpage>943</lpage><pub-id pub-id-type="doi">10.1002/ijc.31357</pub-id><pub-id pub-id-type="pmid">29516506</pub-id></element-citation></ref><ref id="B51-cancers-12-01860"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minn</surname><given-names>A.J.</given-names></name><name><surname>Wherry</surname><given-names>E.J.</given-names></name></person-group><article-title>Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling</article-title><source>Cell</source><year>2016</year><volume>165</volume><fpage>272</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.03.031</pub-id><?supplied-pmid 27058661?><pub-id pub-id-type="pmid">27058661</pub-id></element-citation></ref><ref id="B52-cancers-12-01860"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bronte</surname><given-names>V.</given-names></name><name><surname>Brandau</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>S.H.</given-names></name><name><surname>Colombo</surname><given-names>M.P.</given-names></name><name><surname>Frey</surname><given-names>A.B.</given-names></name><name><surname>Greten</surname><given-names>T.F.</given-names></name><name><surname>Mandruzzato</surname><given-names>S.</given-names></name><name><surname>Murray</surname><given-names>P.J.</given-names></name><name><surname>Ochoa</surname><given-names>A.</given-names></name><name><surname>Ostrand-Rosenberg</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards</article-title><source>Nat. Commun.</source><year>2016</year><volume>7</volume><fpage>12150</fpage><pub-id pub-id-type="doi">10.1038/ncomms12150</pub-id><?supplied-pmid 27381735?><pub-id pub-id-type="pmid">27381735</pub-id></element-citation></ref><ref id="B53-cancers-12-01860"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evrard</surname><given-names>M.</given-names></name><name><surname>Kwok</surname><given-names>I.W.H.</given-names></name><name><surname>Chong</surname><given-names>S.Z.</given-names></name><name><surname>Teng</surname><given-names>K.W.W.</given-names></name><name><surname>Becht</surname><given-names>E.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Sieow</surname><given-names>J.L.</given-names></name><name><surname>Penny</surname><given-names>H.L.</given-names></name><name><surname>Ching</surname><given-names>G.C.</given-names></name><name><surname>Devi</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Developmental Analysis of Bone Marrow Neutrophils Reveals Populations Specialized in Expansion, Trafficking, and Effector Functions</article-title><source>Immunity</source><year>2018</year><volume>48</volume><fpage>364</fpage><lpage>379.e368</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2018.02.002</pub-id><?supplied-pmid 29466759?><pub-id pub-id-type="pmid">29466759</pub-id></element-citation></ref><ref id="B54-cancers-12-01860"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rice</surname><given-names>C.M.</given-names></name><name><surname>Davies</surname><given-names>L.C.</given-names></name><name><surname>Subleski</surname><given-names>J.J.</given-names></name><name><surname>Maio</surname><given-names>N.</given-names></name><name><surname>Gonzalez-Cotto</surname><given-names>M.</given-names></name><name><surname>Andrews</surname><given-names>C.</given-names></name><name><surname>Patel</surname><given-names>N.L.</given-names></name><name><surname>Palmieri</surname><given-names>E.M.</given-names></name><name><surname>Weiss</surname><given-names>J.M.</given-names></name><name><surname>Lee</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>Tumour-elicited neutrophils engage mitochondrial metabolism to circumvent nutrient limitations and maintain immune suppression</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>5099</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-07505-2</pub-id><?supplied-pmid 30504842?><pub-id pub-id-type="pmid">30504842</pub-id></element-citation></ref><ref id="B55-cancers-12-01860"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleinovink</surname><given-names>J.W.</given-names></name><name><surname>van Hall</surname><given-names>T.</given-names></name><name><surname>Ossendorp</surname><given-names>F.</given-names></name><name><surname>Fransen</surname><given-names>M.F.</given-names></name></person-group><article-title>PD-L1 immune suppression in cancer: Tumor cells or host cells?</article-title><source>Oncoimmunology</source><year>2017</year><volume>6</volume><fpage>e1325982</fpage><pub-id pub-id-type="doi">10.1080/2162402X.2017.1325982</pub-id><?supplied-pmid 28811961?><pub-id pub-id-type="pmid">28811961</pub-id></element-citation></ref><ref id="B56-cancers-12-01860"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Migden</surname><given-names>M.R.</given-names></name><name><surname>Khushalani</surname><given-names>N.I.</given-names></name><name><surname>Chang</surname><given-names>A.L.S.</given-names></name><name><surname>Lewis</surname><given-names>K.D.</given-names></name><name><surname>Schmults</surname><given-names>C.D.</given-names></name><name><surname>Hernandez-Aya</surname><given-names>L.</given-names></name><name><surname>Meier</surname><given-names>F.</given-names></name><name><surname>Schadendorf</surname><given-names>D.</given-names></name><name><surname>Guminski</surname><given-names>A.</given-names></name><name><surname>Hauschild</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Cemiplimab in locally advanced cutaneous squamous cell carcinoma: Results from an open-label, phase 2, single-arm trial</article-title><source>Lancet Oncol.</source><year>2020</year><volume>21</volume><fpage>294</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(19)30728-4</pub-id><pub-id pub-id-type="pmid">31952975</pub-id></element-citation></ref><ref id="B57-cancers-12-01860"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tachinami</surname><given-names>H.</given-names></name><name><surname>Nishii</surname><given-names>N.</given-names></name><name><surname>Xia</surname><given-names>Y.</given-names></name><name><surname>Kashima</surname><given-names>Y.</given-names></name><name><surname>Ohno</surname><given-names>T.</given-names></name><name><surname>Nagai</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Lau</surname><given-names>W.</given-names></name><name><surname>Tomihara</surname><given-names>K.</given-names></name><name><surname>Noguchi</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Differences of tumor-recruiting myeloid cells in murine squamous cell carcinoma influence the efficacy of immunotherapy combined with a TLR7 agonist and PD-L1 blockade</article-title><source>Oral Oncol.</source><year>2019</year><volume>91</volume><fpage>21</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.oraloncology.2019.02.014</pub-id><pub-id pub-id-type="pmid">30926058</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="cancers-12-01860-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Distinct transcriptional signatures of neutrophils isolated from cSCC lesions and surrounding skin of DMBA/PMA-treated mice highlight their protumor functions. (<bold>A</bold>) Percentage of neutrophils among CD45+ cells in the skin surrounding papillomas (papilloma skin), within papillomas, in the skin surrounding tumors (tumor skin), and within tumors, <italic>n</italic> = 6 mice per group, * <italic>p</italic> &#x0003c; 0.05, ** <italic>p</italic> &#x0003c; 0.01, Mann&#x02013;Whitney <italic>U</italic> test. (<bold>B</bold>) Microarray analysis of cell-sorted neutrophils: two-dimensional PCA of the 15% most variable probe sets with a minimum log2 average expression of 6. Neutrophils were purified from pools of skin surrounding papillomas (<italic>n</italic> = 6 mice, 2 experiments), skin surrounding tumors (<italic>n</italic> = 9 mice, 2 experiments), papillomas (175 papillomas from <italic>n</italic> = 8 mice, 3 experiments), and tumors (24 tumors from <italic>n</italic> = 5 mice, 2 experiments). (<bold>C</bold>) DEGs in pairwise comparisons. The four contrasts were analyzed based on a minimum log2 average expression of 6, an absolute logFc of at least 1, and an adjusted <italic>p</italic> value <italic>p</italic> &#x02264; 0.05. (<bold>D</bold>) IPA upstream regulator enrichments from the analysis of DEGs in papilloma versus papilloma skin (outer circle), tumor versus tumor skin (middle circle), and tumor versus papilloma (inner circle). The most significant (&#x02212;Log10 &#x02265; 1.39) upstream regulators are shown. A negative z-score (blue) denotes an inhibited pathway. A positive z-score (red) stands for an activated pathway. (<bold>E</bold>) Hierarchical clustering of genes differentially expressed between lesions and their respective skin control identified 10 clusters. The DEGs were selected based on an average log2 expression level across all conditions of at least 7, an absolute log2-fold change &#x02265; 1, and an adjusted <italic>p</italic> value &#x02264; 0.05, in at least one of the two contrasts, papilloma versus papilloma skin and tumor versus tumor skin. (<bold>F</bold>) Average intensity expression levels and adjusted <italic>p</italic> values of <italic>Cd274</italic> (PD-L1), <italic>Vegfa</italic>, <italic>Olr1</italic> (LOX1), <italic>Siglec 5</italic> (Siglec F), <italic>Nos2</italic>, and <italic>Arg1</italic> transcripts are shown, * <italic>p</italic> &#x0003c; 0.05, *** <italic>p</italic> &#x0003c; 0.001, limma differential expression analysis. cSCC: cutaneous squamous cell carcinoma; DMBA: 7,12-dimethylbenz[a]anthracene; PMA: phorbol 12-myristate 13-acetate; PCA: principal component analysis; DEGs: differentially expressed genes; IPA: Ingenuity Analysis Pathways; PD-L1: programmed death-ligand 1; LOX1: lectin-type oxidized LDL receptor 1; Siglec F: sialic acid-binding immunoglobulin-type lectins.</p></caption><graphic xlink:href="cancers-12-01860-g001"/></fig><fig id="cancers-12-01860-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Characterization of TANs (tumor-associated neutrophils) infiltrating mSCC38 tumors. (<bold>A</bold>) Growth kinetic of mSCC38 grafted intradermally in FVB/N mice (<italic>n</italic> = 10 mice). (<bold>B</bold>) Representative hematoxylin-eosin staining of a frozen section, scale bar: 20 &#x003bc;m. (<bold>C</bold>) Proportion of TANs in mSCC38 tumors (<italic>n</italic> = 9&#x02013;12, from three independent experiments), * <italic>p</italic> &#x0003c; 0.05, ** <italic>p</italic> &#x0003c; 0.01, Kruskal&#x02013;Wallis one-way ANOVA. (<bold>D</bold>) Correlation between the frequency of infiltrating Ly6G<sup>+</sup> TANs and tumor volume (<italic>n</italic> = 31). Linear regression curve, spearman r value, and <italic>p</italic> value (95% confidence interval) are shown. (<bold>E</bold>) Representative immunofluorescence imaging of frozen sections of mSCC38 tumor at day 30 post-intradermal implantation showing Ly6G+ neutrophils (green), CD31+ vessels (red), and nuclei (blue). The white dashed line delineates the epidermis&#x02013;dermis junction; scale bar: 10 &#x003bc;m. (<bold>F</bold>) Neutrophil heterogeneity assessed by FlowSOM automatic clustering after t-SNE (t-distributed stochastic neighbor embedding) dimensional reduction using PD-L1, SiglecF, CD54, CD62L, CD11b, and Ly6G. Cell density for the concatenated file of each group is shown on a black to yellow heat scale. FlowSOM clustering was done to separate neutrophil subsets into 49 meta-clusters (MCs). MCs of merged files of each group were overlaid on a t-SNE map. (<bold>G</bold>) MC proportions heatmap. Samples and mean-centered Log2-transformed MC cell proportion were depicted in a heatmap and arranged according to complete linkage hierarchical clustering. (<bold>H</bold>) MC marker expression heatmap. Markers were arranged according to complete linkage hierarchical clustering, but MCs were ordered according to the (<bold>G</bold>) heatmap MC order. (<bold>I</bold>) Tumor-specific MCs. Four MCs (green gates in (<bold>G</bold>,<bold>H</bold>) were back-viewed on a t-SNE-2/t-SNE-2 map). Cell abundance of PD-L1<sup>+</sup>CD54<sup>+</sup>SiglecF<sup>+</sup> neutrophil subset (MC 11 and 17) and PD-L1<sup>+</sup>CD54<sup>+</sup>SiglecF<sup>&#x02212;</sup> neutrophil subset (MC 31 and 13) is presented as the cell proportion among total neutrophils of each group of samples, **** <italic>p</italic> &#x0003c; 0.0001, Kruskal&#x02013;Wallis one-way ANOVA.</p></caption><graphic xlink:href="cancers-12-01860-g002"/></fig><fig id="cancers-12-01860-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Phenotype and function of TANs infiltrating mSCC38 tumors. (<bold>A</bold>) Proportions of neutrophils expressing either PD-L1 and Siglec F alone or together or none of them, day 30 post-intradermal implantation (<italic>n</italic> = 5&#x02013;12 mice, mean &#x000b1; SEM (standard error of mean) from two independent experiments). PD-L1<sup>&#x02212;</sup>Siglec F<sup>&#x02212;</sup> from tumors was significantly downregulated compared to the other subsets, **** <italic>p</italic> &#x0003c; 0.0001; PD-L1<sup>+</sup>Siglec F<sup>&#x02212;</sup> from tumors was significantly upregulated compared to skin and BM (bone marrow), * <italic>p</italic> &#x0003c; 0.05; PD-L1<sup>+</sup>Siglec F<sup>+</sup> from tumors was significantly upregulated compared to skin and spleen, * <italic>p</italic> &#x0003c; 0.05 and to BM, ** <italic>p</italic> &#x0003c; 0.01; PD-L1<sup>&#x02212;</sup>Siglec F<sup>+</sup> from tumors was significantly upregulated compared to BM, * <italic>p</italic> &#x0003c; 0.05; Two-way ANOVA. (<bold>B</bold>) Correlation between the frequency of infiltrating PD-L1<sup>+</sup>Siglec F<sup>&#x02212;</sup>, PD-L1<sup>+</sup>Siglec F<sup>+</sup>, PD-L1<sup>&#x02212;</sup>Siglec F<sup>&#x02212;</sup>, and PD-L1<sup>&#x02212;</sup>Siglec F<sup>+</sup> neutrophils and tumor size (<italic>n</italic> = 12). Linear regression curve, spearman r value, and <italic>p</italic> value (95% confidence interval) are shown. (<bold>C</bold>) Intracellular NAD(P)H (reduced nicotinamide adenine dinucleotide phosphate) levels and (<bold>D</bold>) ROS (reactive oxygen species) production in neutrophils from the BM, spleen, skin, and tumor from mSCC38-bearing mice (<italic>n</italic> = 8&#x02013;17 mice, mean &#x000b1; SEM from two or three independent experiments), * <italic>p</italic> &#x0003c; 0.05, ** <italic>p</italic> &#x0003c; 0.01, *** <italic>p</italic> &#x0003c; 0.001, **** <italic>p</italic> &#x0003c; 0.0001 Kruskal&#x02013;Wallis one-way ANOVA. (<bold>E</bold>) ROS production in TANs from mSCC38-bearing mice day 30 post-intradermal implantation (<italic>n</italic> = 17 mice, mean &#x000b1; SEM from three independent experiments), *** <italic>p</italic> &#x0003c; 0.001, **** <italic>p</italic> &#x0003c; 0.0001 One-way ANOVA. (<bold>F</bold>) Nitrite concentrations measured in supernatants from overnight incubation of highly purified neutrophils from mSCC38-bearing mice (<italic>n</italic> = 18 mice, mean &#x000b1; SEM from three independent experiments), * <italic>p</italic> &#x0003c; 0.05, unpaired two-tailed student&#x02019;s <italic>t</italic> test. (<bold>G</bold>) Arginase activity measured in whole cell lysates from highly purified neutrophils from mSCC38-bearing mice (<italic>n</italic> = 18 mice, mean &#x000b1; SEM from three independent experiments), *** <italic>p</italic> &#x0003c; 0.001, unpaired two-tailed student&#x02019;s <italic>t</italic> test.</p></caption><graphic xlink:href="cancers-12-01860-g003"/></fig><fig id="cancers-12-01860-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>TAN depletion delays cSCC growth and restores antitumor CD8<sup>+</sup> T cell responses. (<bold>A</bold>) left panel: Experimental protocol of the depletion of neutrophils in mSCC38-bearing mice; right panel: Fold change tumor growth between day 17 and indicated times (<italic>n</italic> = 10 mice per group, mean &#x000b1; SEM from two independent experiments), ** <italic>p</italic> &#x0003c; 0.01 Two-way ANOVA. (<bold>B</bold>) Frequencies of proliferating Ki67<sup>+</sup>CD3+CD8+ T cells infiltrating mSCC38 tumors in isotype IgG control or anti-Ly6G-treated mice (<italic>n</italic> = 10 mice, mean &#x000b1; SEM from two independent experiments). ** <italic>p</italic> &#x0003c; 0.01, Mann&#x02013;Whitney <italic>U</italic>-test. (<bold>C</bold>) Frequencies of IFN-&#x003b3;-producing CD3<sup>+</sup>CD8<sup>+</sup> T cells infiltrating mSCC38 tumors in IgG control or anti-Ly6G-treated mice (<italic>n</italic> = 5 mice, mean &#x000b1; SD). * <italic>p</italic> &#x0003c; 0.05 unpaired student&#x02019;s <italic>t</italic> test. Representative contour plots are shown (<bold>B</bold>,<bold>C</bold> left panel). (<bold>D</bold>) Representative IF imaging of frozen sections of mSCC38 tumor at day 30 post-intradermal implantation, scale bar: 10 &#x003bc;m. (<bold>E</bold>) Proportions of PD-1+ cells among CD4+ T cells and CD8<sup>+</sup> T cells from mSCC38-bearing mice day 30 post-intradermal implantation. (<italic>n</italic> = 10&#x02013;13 mice, mean &#x000b1; SEM from two independent experiments). **** <italic>p</italic> &#x0003c; 0.0001 Two-way ANOVA. (<bold>F</bold>) Frequencies of PD-L1+ neutrophils following stimulation of cell-sorted BM neutrophils from naive mice with the indicated TCM and cytokines for 24 h. * <italic>p</italic> &#x0003c; 0.05, *** <italic>p</italic> &#x0003c; 0.001, **** <italic>p</italic> &#x0003c; 0.0001 Kruskal&#x02013;Wallis one-way ANOVA. SD: standard deviation; IF: immunofluorescence; TCM: tumor-conditioned medium.</p></caption><graphic xlink:href="cancers-12-01860-g004"/></fig></floats-group></article>